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Abstract
A side effect of generating an imune system for defense against invading
pathogens is the potential to develop destrctive cells that recognize self-tissues.
Typically, through the "education" of developing immune cells, the organism inactivates
potentially self-destrctive cells, resulting in what is called self- tolerance. I proposed to
explore the molecular mechanisms responsible for the induction and maintenance of
tolerance. Our lab has developed a model of induced immune tolerance to skin and islet
allografts utilizing a donor-specific transfusion of spleen cells and a brief course of anti-
CD40L antibody. Because the diffculty in isolation of tolerant T cells from this system is
prohibitive to performing large screens on these cells directly, I have chosen to study an
in vitro CD4+ Thl cell line, A. , which can be made anergic via stimulation through the
T cell receptor in the absence of costimulation. I hypothesized that anergized T cells
upregulate genes that are responsible for the induction and maintenance of anergy and
therefore exhibit a unque RNA expression profie. I have screened anergic cells using
Affymetrx GeneChips and identified a small number of genes that are differentially
expressed long-term in the anergic population compared to mock-stimulated and
productively activated controls. The results have been confirmed by quantitative RT-PCR
for each of the candidates. One of the most promising, the zinc- fmger transcription factor
Egr- , was verified to be expressed long- term by western blotting, demonstrating perfect
correlation between Egr-2 protein expression and the anergic phenotype. Silencing Egr-
gene expression by siRNA in A.E7 T cells prior to anergy induction rescues the cells
r."
from the inability to phosphorylate ERK- l and ERK-2 and also results in increased
proliferation in response to antigen rechallenge. In this study I report that Egr-2 is
specifically expressed long- term in anergic cells , protein expression correlates inversely
with responsiveness to antigen rechallenge , and that Egr-2 is required for the full
induction of anergy in T cell clones.
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Introduction
A fully developed immune system is essential for an organsm s defense against
invading pathogens. The most comprehensive method to construct a system with
sufficient diversity to combat pathogens to which the host has never been exposed is
through a random assembly of T and B cell receptors. A side effect of using such a
powerful development tool is the inevitable generation of potentially destrctive cells that
recognize self-tissues. Typically, through the "education" of developing imune cells
the host inactivates potentially self-destrctive cells , resulting in what is called "self-
tolerance . Occasionally, self-tolerance is disrupted and the host experiences autoimmune
destrction of self-tissues, as is seen in diabetes , multiple scleross, lupus, and rheumatoid
arhrtis. Through an understanding of tolerance induction and maintenance, methods are
currently being developed to "re-educate" the immune system. Treatments developed to
suppress the immune response will be usefu to reverse and prevent autoimmune disease;
additionally, these treatments could be modified to control alloimmune responses to
tissue and organ transplants. Conversely, treatments to enhance imune responsiveness
by breaking tolerance wil be useful in vaccination and induction of tumor immunity.
Both T and B cells are important in the host immune response and both have been
implicated in autoimune destruction. In many cases, B cells require T cell help or
permission" in order to become effectors; accordingly, many feel that a thorough
knowledge of T cell tolerance mechansms will allow interventions that wil also curb B
cell- mediated destrction. Aside from minor points, only tolerance associated with T
cells will be discussed.
Two general methods of mediating self- tolerance have been described. Both
methods central and peripheral tolerance, appear to be necessar to control the imune
system to maintain tolerance (1). Likewise, both methods are being studied and
manpulated to induce tolerance at times when it has failed (such as in autoimunty) or
when it would be medically advantageous to the individual (durig allogenic
transplantation). Central tolerance occurs in the thymus as cells enter the organ and then
percolate throughout, becoming exposed to a variety of self-antigens presented by
resident antigen presenting cells. Potentially autoreactive T cells with high affmity for
self-antigen are selectively deleted following engagement with the presenting cells; this
process is termed negative selection (2). It has been demonstrated that a number of
autoimune mouse models (e.
g. 
the NOD lIuse) demonstrate an inability to delete
certain autoreactive T cells and this results in tissue destrction in the periphery (3),
suggesting that defective central tolerance through negative selection is responsible for
autoimmune disease. However, it has also been reported that normal healthy individuals
also host T cells in the periphery that recognize self-antigens; these autoreactive cells are
evidently unable or unwiling to effect an imune response (4;5).
The ability to control autoreactive T cells once they escape central tolerance and
enter the periphery proposes a requirement for a second mechanism of tolerance
peripheral tolerance. In this case, T cells that escape deletion in the thymus , typically
low affinity autoreactive T cells (6), are made unesponsive in the periphery. Peripheral
tolerance has been reported to be mediated in a number of ways: 1) Ignorance; when
potentially autoreactive T cells released into the periphery never encounter antigen
because the antigen is expressed in an immune-privileged site or it never reaches the
threshold required to trgger a response. 2) Phenotype skewing; T cells are activated but
progress to a non-pathogenic phenotye, such as cytokine deviation; 3) Peripheral
deletion; T cells undergo apoptosis in response to exogenous tolerizing signals. 4) T cell
suppression; the recruitment of antigen-specific T cells trained durng thymc
development to prevent the activation and proliferation of other potentially autoreactive
cells. And finally, 5) Unresponsiveness or anergy; cells are parially stimulated in such a
way that they remain unesponsive to full stimulation at a later time, when they have the
potential to destroy self tissues (7).
When these mechanisms fail to control autoreactive T cells and autoimmunity
ensues, one option to cure the disease is transplantation of the destroyed tissue (i. e. 
islets in the case of tye I diabetes melltus). However, a metlDd must be utilized to
control imune alloreactivity to the foreign transplanted tissue as well as the recurrence
of autoimunity. Our lab has developed a model of induced imune tolerance to islet
allografts utilizing a donor-specific transfusion of spleen cells and a brief course of anti-
CD40L antibody into a chemically- induced diabetic host (8). The result is permanent
survival of the graft and normalization of blood glucose, effectively curing the host of
diabetes in the absence of general imunosuppression. We believe that this protocol
involves one or more of the mechanisms of peripheral tolerance described above
specifically T cell deletion (9), suppression, and anergy.
';/
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I have chosen to study the state of long- term unesponsiveness in perip eral T
cells termed anergy. The anergic state has been demonstrated in a number of models of T
cell stimulation, both in vitro and in vivo. While these models utilize different methods of
induction and vary somewhat in their characteristics, it is widely accepted that they
represent actual events that occur in vivo during the induction of tolerance to peripheral
tissues.
History of anergy
T cell clones, established from mouse or human peripheral T cells and maintained
in vitro, can be stimulated by antigen presenting cells (APC' s) pulsed with T cell-specific
antigen; this in vitro stimulation is believed to mick T cell activation in vivo. APC's-
which consist of B cells, macrophages, or dendrtic cells-stimulate CD4+ T cells via
peptide presented on the major histocompatibility complex II (MHC II) which crosslins
the T cell receptor (TCR); additionally, cells receive costimulation through the T cell
coreceptor CD28 by the APC ligands B7 - 1/2. This stimulation plus costimulation results
in IL-2 production and proliferation in the T cells (Figure l).
.;/
Legend to Figure 1: T cell stimulation through APC peptide presentation. A stimulatory
signal is generated through the TCR of a CD4+ T cell via specific peptide presented on
the MHC II of the APC. In addition, a costimulatory signal is provided through ligation
of CD28 on the T cell by B7. 1/2 on the APC. The result is IL-2 production and
proliferation in the T cell.
Antigen-induced T cell hyporesponsiveness was first observed by Feldmann and
colleagues in 1983 when human CD4+ Thl clones reactive against the influenza HA
epitope were pulsed in vitro with moderate amounts of peptide in the absence of
syngeneic APC' s; they were later hyporesponsive to rechallenge with peptide presented
on APC' s (10). Human T cells are unique in that they are able to process soluble antigen
and present to other T cells via MHC class II molecules; mouse cells cannot. These
makeshift antigen-presenting cells lack B7. 1/2 costimulation.
This phenomenon was then fuher defined and characteried as T cell anergy by
Schwarz and colleagues in 1987. They observed that mouse T cell clones stimulated in
vitro did not respond optimally when the APC' s were chemically modified with protein
crosslinker l-ethyl- 3-(3-dimethylaminopropyl)-carbodiimide (ECDI) (11). In addition
when these T cell clones were rested following the initial stimulation and later exposed to
fully fuctional APe's plus antigen , they were surprisingly unesponsive-producing
very low levels of IL- 2 and failing to proliferate normally (11). A similar result was
observed when T cell clones were stimulated with purfied MHC molecules incorporated
into planar lipid membranes plus antigen (12), with Conconavalin A (Con A) in the
absence of APC' s (13), or with calcium ionophore treatment (14;l5). This
hyporesponsive phenotype was defined as T cell clonal anergy and the common event in
the various anergizing stimuli was proposed to be a lack of costimulatory signal through
CD28 (16). This hypothesis was confirmed when the anergizing stimulus could be
mimicked by treatment of the T cells with platebound anti- TCR mAb (anti-CD3) in the
absence of APe's (17) and anergy induction could be avoided if anti-CD28 mAb was
-,p
included in the stimulation, resulting in increased IL-2 production and proliferation
(18;l9).
Additional studies , however, have demonstrated that stimulation of T cell clones
by fully competent APC' s (with normal costimulatory ability) but presenting altered
peptide ligands could also induce the anergic state. In this form of stimulation, the known
peptide recognized by the T cell clone was mutated at a single amino acid until an altered
peptide was found that failed to induce proliferation. A number of these altered ligands
induced anergy in the T cells (20). These anergizing peptides were termed "parial
agonists" as opposed to "agonists" which activated the T cells or "antagonists" which
failed to induce either proliferation or anergy. These methods of anergy induction are
sumared in Figue 2.
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Legend to Figure 2: Methods of anergy induction in CD4+ T cell clones in vitro. A) T
cells are activated and anergy is avoided following stimulation through the TCR and
costimulation through CD28. B) Anergy results following stimulation through the TCR
alone. C) Anergy is induced following TCR stimulation with a "parial agonist" even in
the presence of costimulation through CD28.
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In all of the anergy models described above, it was observed that the T cell clones
failed to produce IL-2 following the anergizing stimulus and that anergic T cells could
recover antigen responsiveness following treatment with exogenous IL-2 (2l). Later
work showed that even full stimulation of T cell clones in vitro could result in anergy
induction if IL-2 signaling was interrpted using anti-IL-2 or anti-IL-2-receptor blocking
antibodies durg stimulation (22). If T cells were fully stimulated but the IL-2 was
washed out 12h after stimulation to maintain a low concentration, the T cells did not
proliferate and became arergic (23). In parallel, anergy induction could be prevented by
signaling through the 
'Y c chain of the IL-2 receptor via cross-ling with aIL-
antibody (24). All of these reports demonstrated that IL-2 was necessary to prevent
anergy induction, but it was unclear what molecular events following IL-2 receptor
signaling could both prevent anergy induction and abrogate established anergy in
unesponsive clones.
More recent work has demonstrated that preventing proliferation with rapamycin
a drg that blocks G 1 to S phase cell cycle transition, induced anergy in fully stimulated
T cells. Hydroxyuea, a drg that arrests cell growth in the S phase, did not (25). It was
apparent from these experients that normal T cell stimulation results in the upregulation
of "anergic factors" and that these factors are then downregulated with proliferation or
more specifically, Gl to S phase transition; only a stimulated cell that has proliferated
avoids anergy. In summary, T cell anergy results from the upregulation of "anergic
factors" following TCR engagement and failure to progress from G 1 to S phase transition
(Figue 3).
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Legend to Figure 3: Model of T cell anergy and the induction of "anergic factors
proposed by Powell et al. (25). TCR stimulation results in multiple signaling processes
that accumulate in signal 1. One of the effects of TCR signaling is the generation of
anergic factors" that mediate anergy. CD28 signaling provides an additional signal
(signal 2) that is additive to the first, resulting in IL-2 transcription, production and
release. Following autocrine signaling of IL-2, cells undergo cell cycle G S phase
transition and proliferation. IL-2 production is severely impaired following TCR
stimulation in the absence of CD28 signaling (lack of signal 2) and results in anergy. In
the presence of full costimulation, peptide partial agonists do not produce suffcient
signaling to result in IL-2 production, but do induce anergy and, therefore
, "
anergic
factors" (signaling progresses only to " ). The presence of rapamycin, which blocks cell
cycle in Gl , induces anergy even in productively stimulated cells while hydroxyurea
which blocks cell cycle in S , does not. Cyclosporie A (CSA), which blocks early TCR
signaling, prevents both activation and anergy. The authors conclude that "anergic
factors" are induced at signal step "B" and that G S phase transition (resulting from
productive stimulation or exogenous IL-2 treatment, blocked by rapamycin but not
hydroxyuea) causes inibition or degradation of these factors.
Primer on the biochemical events following T cell
activation
In order to more easily describe the biochemical events necessary for anergy
induction and maintenance, I wil provide a brief description of the biochemical events
that occur upon T cell activation, followed by a figure in sumary. Following TCR
engagement, the subunits of the TCR become phosphorylated by the Src family kinase
Lck. These phosphorylated motifs then recruit the tyosine kinase Zap- 70 which then
phosphorylates the adaptor molecules LAT and SLP-76. These adaptors then recruit other
proteins including phospholipase C (PLC) and son of sevenless (SOS), forming a large
complex at the cell surface that results in the activation of three signaling pathways that
converge on the IL-2 promoter, activating transcription. A brief description of the three
pathways is as follows: 1) Ras is activated by its exchange factors SOS and RasGRP.
RasGRP is dependent on PKC which in turn is activated by diacylglycerol (DAG), a
cleavage product of the membrane lipid PIPz generated by PLC. Activated Ras recruits
Raf and these proteins lead to the activation of a number of kiases that activate the
mitogen-activated protein (MAP) kinases ERKl/2 , JNK, and p38. These MAP kinases
activate transcription of, and directly phosphorylate , the transcription factors fos and jun
which dimerize to form AP- , a trascription complex required for IL-2 activation. 2)
MAP kinase kiase kinase (MAPKK) is also activated by PKC and leads to the
degradation ofIKB , an inbitor ofNFKB , which leads to the migration ofNFKB into the
nucleus for activation of IL-2 transcription. 3) In addition to DAG, PLC generates
another cleavage product IP3, which induces the release of intracellular Ca ++ stores. This
calcium in tu activates cell surface Ca ++ channels and results in a large flux of calcium
into the cell. The increased Ca ++ concentration activates the phosphatase calcineurin
which dephosphorylates NFAT allowing it to enter the nucleus and activate IL-2
transcription (26).
The previous discussion of anergy induction methods suggested an important role
for CD28 costimulation in IL-2 production and anergy avoidance. Eviderxe suggests that
the biochemical effects ofCD28 ligation on IL-2 transcription are three- fold: l) PI3
kiase (PI3K) is recruited to CD28 resulting in activation of Akt and increased
MAPKK activity in pathway 2 , resulting in NFKB activation (26). 2) The Ca ++ flux
following TCR ligation is prolonged by CD28 (however CD28 stimulation alone has no
effect on Ca ++ flux) with a net increase in pathway 3 accumulating in NF A T activation
(27). 3) IL-2 mRA is stabilized, allowing message to accumulate to high levels and
results in increased IL-2 protein production (28). These concepts ofT cell activation
resulting in IL-2 production are sumarzed in Figue 
TCR C028
;;31
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Figure 4
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Legend to Figure 4: Signaling events following T cell activation.
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Signaling events required for anergy induction
As described above, Powell et al. demonstrated that anergy results from TCR
engagement in the absence of proliferation (25). Since TCR signaling results in the
induction of three separate pathways, these pathways have been examined to determine
which are required for the induction of anergy. Jenkns et al. showed that calcium
signaling (pathway 3 in Figue 4) is essential for the induction of the anergic state.
Cyclosporine A (CSA), a drug that blocks early T cell signaling at calcineurin and
prevents T cell activation, prevents T cell anergy induction as well (17). Anergy
induction is also blocked by EGT A, a calcium chelator (29). Calcium ionophore
treatment, resulting in increased intracellular calcium levels, can induce anergy (15). One
of the major consequences of calcium flux following stimulation in T cells is the
activation of the transcription factor NF AT. It was suggested that, downstream of calcium
flux, NF A T was responsible for the induction of the anergic factors described in the
model. In support of this hypothesis, Macian et al. reported that T cells from NFAT-
deficient mice (the predominant NFAT in resting T cells) are resistant to anergy
induction and that cells transfected with a constitutively active NFATI show reduced IL-
2 production following anti-CD3 and anti-CD28 stimulation. This occurs even when
NFATI is modified to prevent interaction with AP- , suggesting that, independent of AP-
, NF AT is capable of inducing anergic factors (15).
The MAP kinase cascade (pathway 1 in Figue 4) is made up of three parallel
pathways-ERK, JNK, and p38. Chemical inhibitors of two of the three pathways
(SB203580 blocks p38 and PD90859 blocks ERK- l and ERK-2) do not prevent anergy
I."t:
induction. Also, a T cell line derived from the JNK 2 - , JNKI dominant negative mouse
could be anergized with anti- TCR antibody (L. Luu, 1. Powell & R.H. Schwarz
unpublished data, described in (30)). While calcium mobilization resulting in NFAT
activation is required for the induction of anergy, signaling through the MA kiase
cascade and the transcription factor AP- l is not. It is curently unclear what role, if any,
NFKB (pathway 2 in Figure 3) plays in the induction of anergy factors. Since CD28 plays
an importt role in augmenting NFKB activation and CD28 signaling is tyically absent
durng anergy induction, it is possible that NFKB is also not required for anergy
induction. Supporting this is the fact that calcium ionophore alone can induce anergy.
Figue 5 incorporates the hypothesis that NFAT activation alone is required for anergy
induction.
TCR C028
;./
'e 'e
.. 
Anergy
' Factors
Figure 5
Legend to Figure 5: Anergy factors are upregulated by NFAT following T cell
activation.
Molecular and biochemical observations in anergy
maintenance
Since anergy was first described, many groups have been workig to elucidate the
molecular and biochemical events that are required for the maintenance of the anergic
state. One of the first observations made in stimulated anergic cells is that they fail to
make IL-2 (17). Since IL-2 is an important cytokine for T cell proliferation, this could
explain the lack of proliferation in fully stimulated anergic T cells. However, it was
unclear what events between T cell stimulation and IL-2 production were altered.
First, the expression of the TCR was examined. Although most T cells
downregulate their TCR in response to stimulation, they restore normal expression after
5 days; anergic cells are no different (31). Following stimulation, responsive T cells
experience a rapid influx of calcium followed by activation of calcineuri
dephosphorylation and mobilization ofNFAT into the nucleus, and activation ofIL-
transcription. While one group reported that anergic cells have constitutively elevated
calcium levels (32), Mondino and colleagues have since shown convincingly that anergic
cells have normal calcium flux as well as NF A T mobilization and binding following
stimulation (31).
In parallel to the calcium-NFAT pathway, the Ras/MAP kinase pathway becomes
activated in responsive T cells. This consists of activation of SOS and RasGRP
activation of Ras, and the phosphorylation and consequent activation of the MAP kiases
ERK, JNK, and p38. These kinases phosphorylate fos andjun which dimerize to form
AP- l and activate transcription ofIL-2. Stimulated anergic T cell clones are defective in
- ':
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AP- l-mediated transcription (23) and, more specifically, in entr of the AP- l subunits c-
fos, fosB and jun into the nucleus (31). It is unclear if the defective nuclear entr is due
to transcrip tional repression, translational repression, or a traffcking defect.
Upstream of the activation of the AP transcription factors, each of the three
parallel pathways in the MAP kiase cascade-ERK, JNK and p38-is altered. While
they are normally activated in response to TCR signaling, the kinases remain inactive in
stimulated anergic T cell clones (33;34). In addition Ras, upstream effector of the MAP
kiase cascade, was shown to remain in its inactive, GDP-bound form following
stimulation. However, the upstream effector son of sevenless (SOS), which facilitates
GTP loading on Ras, was activated normally (35). This led to speculation that anergic
cells contain a Ras GTPase Activating Protein (GAP) that is responsible for converting
Ras-GTP to Ras-GDP, preventing its kinase activity.
Opposing this idea, Gajewski and colleagues demonstrated that anergic cells
contain increased activity of the signaling kinase Fyn (32). Its association with Cbl and
the CrkLC3G complex results in constitutive activation of Rap- , which was
demonstrated to inhibit the ability of Jurkat T cells to upregulate IL-2 in response to
stimulation. Because activated Rap- l can associate with Rat: 1 protein kinase and prevent
its interaction with Ras, the authors argued that activated Rap- l was responsible for
preventing Ras activation in anergic cells (36). However, Fyn deficient mice can be
anergized (N. Nabavi and R.H. Schwartz unpublished--escribed in (30)), lending
credibility to the speculation that Ras hypoactivity in anergy is due to an as yet
undentified Ras GAP.
These observations suggest that the defect in producing IL-2 in anergic t cell
clones is simply due to a defect in Ras activation, resulting in a hypoactive MA kinase
cascade, and ultimately in defective mobilization of the AP - l transcription complex.
However, in addition to the biochemical signaling block focused around Ras and the
MAP kinase cascade, Powell and colleagues argued that the IL-2 promoter contains a site
180) that is susceptible to active repression represented by a shift in binding from AP-
transcription factors (activating) to cAMP Response Element-Binding protein/cAMP
Response Element Modulator (CREB/CREM) factors (repressing) (37). The
CREB/CREM repressor complex is predominant in both resting cells and stimulated
anergic cells. It is possible that a competition of transcription factors occurs at this site
with negative regulators (CREB/CREM) predominating in resting cells (to prevent IL-2
transcription in the absence of signaling) and in stimulated anergic cells. Positive
regulator AP- l binding is predominant in stimulated responsive cells. It is unclear
whether the imbalance observed in anergic cells is due to a paucity of AP- l factors, an
excess of CREB/CREM factors, or an active regulator that is responsible for shifting the
balance (through phosphorylation ofCREB/CREM, for example). A sumary of the
varous signaling and transcriptional blocks identified in fully stimulated anergic cells is
described in Figure 6.
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Legend to Figure 6: Signaling and transcription blocks in anergic cells exposed to full
stimulation.
Evidently, mechanisms other than the block in Ras activation contrbute to
hyporesponsiveness in anergic cells. Another study supporting this hypothesis is a recent
one by Crespi and colleagues who transfected T cells with a Ras mutant that is
constitutively active (Ras (Leu61)). While transfected T cells elicited TCR- independent
activation of the Ras- Raf- ERK pathway and conferred T cells with the ability to secrete
IL-2 in response to stimulation with Ca ++ ionophore alone, it was insufficient to confer
resistance to anergy induction via chronic TCR engagement (38).
In order to identify genes responsible for anergy, Korthauer et al. performed
differential display analysis on anergic cells using four different methods of anergy
induction (39). One of the candidates reported by the group was General Receptor of
Phosphoinositides 1 (Grpl), a cell membrane protein first discovered in the lab of
Michael Czech at the University of Massachusetts Medical School. Grp 1 is a member of
the cytohesin famly that selectively binds the membrane signaling intermediate PIP3 and
regulates cellular adhesion and membrane traffckig (40). When Grpl was retrovirally
transduced into primar T cells they exhibited normal proliferation and cytokie
production. However, transduced cells rapidly lost expression of the protein, suggesting
that Grp 1 plays a role in limiting T cell expansion or surival. Anergic cells cannot home
to the marginal zone of germinal centers in vivo (41); it is possible that the adhesion
characteristics of Grp 1 mediate this fuction.
Another group identified a novel gene that was induced in an anergic CD4+ Thl
cell. line, named Gene Related to Anergy In Lymphocytes (GRAIL). It was induced after
4 hours of stimulation with engineered fibroblasts that expressed MHC class II witrout
co stimulatory molecules. GRAL was not expressed in unstimulated cells or in fully
stimulated cells and its expression was inhbited by CSA. However, GRAIL was not
expressed after l8 hours ofanergizing stimulation and so is only transiently expressed in
anergic cells. GRAL is an E3 ubiquitin ligase which, when overexpressed in T cells
inhibited IL-2 production in response to anti-CD3 plus anti-CD28 antibody activation.
This inhibition ofIL-2 production was dependent on an intact endocytic pathway (42).
Boussiotis et al. reported that, secondary to an increase in intracellular cAMP, the
cell cycle regulator p27kipi was upregulated in anergic human T cell clones as well as
alloreactive mouse T cells tolerized in vivo. Overexpression ofp27kipi in T cells inbited
IL-2 production. They observed that p2tipi interacted with JAB 1 in anergic cells but not
unstimulated controls and proposed that p27kipl maintained T cells in the anergic state by
sequestering JAB 1 in the cytoplasm, preventing its interaction with c-Jun and Jun.
JAB 1 stabilizes the interaction of Jun activators with AP- l sites , allowing transcription of
IL-2 (43). It was reported by others that, in mouse T cell clones, increased p27kipl levels
did not correlate with the anergic phenotye. Although treatment with exogenous IL-2
downegulated expression ofp27kipI , the amount ofIL-2 necessary to downregulate this
protein was much lower than that required to prevent the induction of anergy. They also
showed that while overexpression ofp27kipi was able to decrease IL-2 promoter- induced
expression, physiological levels of this protein had no effect on the IL-2 promoter. Lastly,
they demonstrated that T cell lines from p27kipl knockout mice were as susceptible to
anergy induction as those from mice heterozygous for the gene (44).
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None of the proteins in the studies described above fits the profie of an "anergic
factor" predicted by Powell et al. (25) and none has been demonstrated to be required for
anergy induction or maintenance.
Anergy in primary T cells
Anergy is not limted to T cell clones in vitro. In fact, the characteristic
unresponsiveness and lack of IL-2 production of anergy has also been observed in
priary T cells from the mouse and human, both in vitro and in vivo; demonstrating the
far-reaching implications of understanding anergic mechansms to the management 
imune tolerance in the organsm. The following section first describes experiments that
anergized priar T cells ex vivo and then studies that reported the induction of T cell
anergy m VIVO.
Mouse and human primary T cells ex vivo
Chai and Lechler induced anergy in highly purified mouse primar CD4+ T cells
in vitro via stimulation with platebound anti-CD3 mAb. While a large number of these
cells died by apoptosis, the remaining viable cells did not proliferate and failed to make
IL-2 when rechallenged with Con A but were hyperresponsive to exogenous IL-2.
Anergy induction was seen in both naIve and memory T cells in this study and was
inhbited by cyclosporine A (45). Anergy- like unesponsiveness has been demonstrated
in human peripheral blood mononuclear cells (PBMC' s) in an MLR in the presence of
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inhibitors of costimulation such as CTLA4-Ig (46) and in freshly isolated PBMC'
stimulated with anti- TCR antibody in the presence of IL-l 0 (47).
Wells and colleagues observed an interesting relationship between anergy and cell
division history as well as anergy and CTLA-4 signaling in priary mouse T cells
stimulated in vitro. Pooled spleen and lymph node cells were labeled with CFSE and
stimulated in vitro with soluble anti-CD3 mAb alone or in combination with anti-CD28
mAb (to enhance co stimulation) or CTLA4-Ig (to block costimulation through APC B7
interaction with T cell CD28). The cells were stimulated for 4 days, rested for 48 hours
and then sorted based on CFSE fluorescence. Sorted T cells were then rechallenged with
irradiated syngeneic APC' s plus soluble anti-CD3 mAb with or without IL-2. They
observed that when cells were stimulated with anti-CD3 mAb in the presence of CTLA4-
Ig (blocking co stimulation through B7 molecules), they divided much less than those
stimulated with anti-CD3 mAb alone. In addition, these cells were hyporesponsive to
rechallenge with anti-CD3 mAb plus fresh irradiated syngeneic APC' s (now with
available B7), as assessed by CFSE dilution and by IL-2 production. This
hyporesponsiveness to secondar stimulation was observed regardless of their
proliferation history. However, when provided with exo genous IL-2 in addition to anti-
CD3 mAb, the cells proliferated normally (48). These observations support those seen in
T cell clonal anergy but challenge the notion that cell division in the absence of
co stimulation can result in the abrogation of the anergic phenotye. However, as R.
Schwarz notes in a review of anergy, this group only isolated cells that had proliferated 0
times or 2 times to assess for responsiveness based on cell division durng the secondar
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stimulation. He suggests that maybe cells stimulated under these conditions require more
total time spent in G 1 to S phase transition in order to circumvent the anergic state , and
that the authors could also look at cells that had divided 3 or 4 times (30). Secondly, the
authors sorted T cells according to cell division history following stimulation with anti-
CD3 alore (with B7 available for co stimulation) and rechallenged with anti-CD3 plus
irradiated syngeneic APCs with or without IL-2. Under these circumstances, a cell that
failed to divide, regardless of the presence of costimulation, was hyporesponsive to
rechallenge. This supports the conclusions of Powell et al. (25) that co stimulation alone is
not suffcient for anergy avoidance, but that cell division is also required to avoid anergy.
These cells, however, were also refractory to proliferation even when exogenous IL-2
was included in the secondary stimulation. This appears to be a deeper level of anergy,
and the authors suggest that it is a result ofB7 stimulation ofCTLA-4 in the priar
stimulation of the cells that fail to divide (48). These observations led the authors to
conclude that anergy avoidance requires a combination of both costimulation and cell
division.
Mouse primary trans2enic (T2) T cells in vivo-soluble peptide
Marc Jenks and his group developed a transgenic model to study T cells
tolerized in vivo, their persistence in the host, and traffckig of these cells compared to
stimulated cells. Na'ive mouse DO II transgenic T cells were adoptively transferred into
syngeneic wild-tye recipients; the recipients were then treated with soluble intravenous
OV A323_339 peptide (tolerizing stimulus), left untreated (unstimulated) or treated with
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subcutaneous peptide plus adjuvant (stimulated). The tolerized T cells rapidly expanded
and then contracted in vivo; the suriving cells were hypoproliferative and defective in
IL-2 production upon rechallenge with peptide in vitro and in vivo. These tolerant cells
persisted for at least 3 weeks and for as long as several months in vivo, regaing
fuctional capability over this long rest period if not rechallenged with peptide. Further
in contrast to cells activated with peptiie in complete adjuvant, tolerized cells did not
efficiently accumulate in the lymph nodes, suggesting that tolerant cells localize
differently than responsive cells in vivo (49).
Mouse primary Te: memory T cells in vivo-soluble peptide
Mirshahidi et al. showed that pried (memory) mouse T cells could be made
anergic. They isolated 6.5 TCR transgenic CD4+ T cells that recognize the HAIl 0- 120
peptide presented on I- , adoptively transferred the cells into BlO.D2 recipient mice
and pried the mice with the HA peptide in complete adjuvant. Five weeks later they
treated the mice with low-dose soluble peptide in incomplete adjuvant to induce
tolerance. With this treatment, the memory transgenic T cells were hypoproliferative and
defective in IL-2 production when rechallenged with peptide in vitro. The tolerant cells
expanded, however, when cultured with recombinant IL-2 (50).
Mouse primary Te: T cells in vivo-tissue whole protein expression
Tanchot et al. adoptively transferred transgenic T cells that recognize PCC
presented in the context ofI- into a transgenic IDst that expressed the whole PCC
protein under control of an MHC class I promoter, conferrng constitutive expression of
the antigen in the host. The transferred transgenic T cells experienced an intial expansion
and then deletion phase; the remaining cells manifested an 85-95% reduction in all
cytokine production and decreased proliferative response to antigen in vitro. Ifthe cells
were transferred into a second host without antigen, they partially regained
responsiveness. If transferred into a second ho st that expressed the antigen, the cells
initially regained responsiveness , but then slowly entered into an even deeper state of
tolerance, demonstrated by fuher reduced cytokine production and proliferation with
rechallenge in vitro (51).
Mouse primary non- Te: T cells in vivo-s uperantie:en
In a non-transgenic model of in vivo tolerance, mice were injected with
staphylococcal enterotoxin B (SEB) to stimulate T cells in vivo in a nonspecific maner
resulting in anergy. SEB is a superantigen that binds the TCR and MHC proteins
laterally, inducing potent activation of a large number of T cells in the host. When T cells
were stimulated with SEB in vivo, they expanded and then contracted, presumably by
apoptosis. The remaining T cells were unresponsive in vitro to TCR ligation with eitrer
the superantigen or anti- TCR antibodies, failing to proliferate and make IL-2.
Interestingly, these cells were also unable to respond to exogenous IL-2 (52;53).
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Human primary T cells in vivo (in SCID mouse)
In an effort to reconstitute a SCID mouse with a human imune system, human
peripheral blood leukocytes (PBLs) were injected and analyzed over four weeks. The cell
population initially expanded but later contracted, leaving a population of human T cells
that remained long-term in the host. The model was not paricularly useful, however
because the remaining cells could not mount a response when challenged with foreign
tissue. When the suriving cells were rechallenged in vitro with anti-CD3 and anti-CD28
mAb, they could not proliferate or make IL-2. The cells did proliferate, however, when
treated with exogenous IL-2 , suggesting that they were anergic. After suffcient IL-2
stimulation in vitro, the T cells reacquired the ability to respond to stimulation with
mitogens or mouse proteins presented on syngeneic APCs (54).
These reports demonstrate that anergy is not just an in vitro phenomenon of T cell
clones; there is a role for T cell anergy in priar cells in vitro and in vivo.
T cell suwression-is anergy involved?
T cell suppressor function has recently been demonstrated in a number of T cell
subtyes in vitro and in vivo. One of the most potent of the T cell suppressors exhibits
constitutive CD25 expression. These cells have been shown to suppress CD25- T cells to
a high degree when both are present and stimulated in vitro by APC's or by antibody-
coated beads. This suppression requires cell-cell contact. Once the suppressor cells have
been activated, suppression is mediated in an antigen-independent manner. CD25+
suppressor cells have been described as "anergic" as they do not proliferate when fully
stimulated in vitro (anti-CD3+anti-CD28 mAb or matue allogeneic dendrtic cells) but
wil proliferate modestly when stimulated in the presence of IL-2 (55). However, they do
not exhibit "classical" anergy as they retu to an anergic state even after IL-2- induced
proliferation.
Ermann and colleagues have proposed that CD25+ suppressor cells mediate
suppression by inducing anergy in the CD25- target cells. They demonstrated that when
CD25+ suppressors and CD25- targets were stimulated in co-cultue, CD25- cells
upregulated transcription of GRAL, a gene specifically induced in anergized T cells that
inhbits IL-2 production (described above). IL-2 treatment of the suppressed cells
abrogated suppression and permitted proliferation, also implicating the anergic state in
the failed proliferation of the CD25- targets (56).
In some cases, originally nonsuppressive T cells that were anergized in vitro gain
suppressive ability, both in vitro and in vivo. The lF8 T cell line, derived from NOD
mice and alloreactive for the amino acid substituted H2- molecule (NOI)P), was
rendered anergic in vitro with platebound anti-CD3 mAb. Subsequently, they were
unresponsive to stimulation in vitro with NOI)P spleen cells but remained responsive to
exogenous IL-2. When anergic lF8 cells were mixed with responsive (unstimulated) lF8
cells and then exposed to NOI)P splenocytes in vitro, the proliferation of the responsive
cells was suppressed. This suppression required cell-cell contact; when anergic cells were
separated from the responsive cells in a transwell, no suppression was observed. When
NOD recipients are first primed with NOJjsp spleen cells and then transplanted with
NODasP tail ski, rejection is typically seen within 10- 15 days. However, when recipients
'i'
received anergic IF8 cells on days 1 and 5 post-grafting, a prolongation of graft survival
to 25-30 days was observed, demonstrating that anergic IF8 T cells had some suppressive
activity in vivo as well (57).
These studies implicate anergy in T cell suppression. It is unclear whether this
role is in the suppressor T cell itself, in the target of suppression, or both.
Evidence for anergy in tolerance to alloanti
Protocols developed to induce tolerance to alloantigens will be useful in
transplantation of allografts. Our lab has developed a protocol utilizing anti-CD40L mAb
and a donor-specific transfusion of splenocytes to induce long-term donor-specific
tolerance to alloantigen (8). Another group cultued a mixed lymphocyte response (MLR)
with purfied B6 CD4+ T cell responders and irradiated bm12 stimulators (which differ
from B6 at three amino acids in the IA region of the MHC class II); anti-CD40L mAb
was added to induce tolerance in the B6 responder T cells. While including anti-CD40L
in the MLR prevented proliferation of the responders in the primar MLR, the cells were
also hyporesponsive after being washed, rested, and stimulated in a secondar MLR in
the absence of the antibody. When IL-2 was included in the priar MLR, it prevented
induction of tolerance. In addition, exogenous IL-2 restored the proliferative response of
toleried responders in the secondary MLR. The response of tolerized cells to third part
stimulators was much less affected, demonstrating specificity for the tolerizing stimulus.
This result suggests that the use of anti-CD40L to tolerie T cells induces anergy in
potentially alloreactive T cells (58).
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Lechler and colleagues have proposed that anergy is induced in vivo in hum
peripheral tissues by antigen presentation on MHC class II positive cells that lack
costimulatory ability. They have observed that cardiac and renal transplant recipients
harbor alloreactive T cells in their periphery that remain unesponsive when stimulated in
vitro with donor alloantigen but can recover responsiveness when treated with exogenous
IL-2. They exhbit no change in response to third part stimulators. Their model is that
inflamed parenchymal tissues upregulate MHC class II molecules in response to IFN-
secretion but lack co stimulatory molecules , inducing a hyporesponsive or "anergic" state
in potentially alloreactive T cells in the classical "stimulation without co stimulation
sense (59).
HYothesis/ 
A12foach
I hypothesized that anergic T cells exhibit a unique RNA expression profie.
Previous data from others (25) indicates that upregulated proteins or "anergy factors" are
induced following T cell activation, are sensitive to CSA, and are downegulated with
proliferation following either full activation or exposure to exogenous IL-2. I determined
to screen for anergic factors with these characteristics by analyzing the RNA expression
profie of anergic cells compared to mock-stimulated and fully activated controls at three
times: before, during and after proliferation in the activated population. RNA analysis
was performed using Affymetrix GeneChips, a method that allows the simultaeous rapid
screening of approximately 36 000 expressed sequences. Factors differentially expressed
in anergic cells and possessing the expected characteristics were fuher examied for
functionality in the anergic phenotye.
Materials and Methods
Cells
A.E7 (a generous gift from R. Schwarz, NIH, Bethesda, MD) is a CD4+ Thl
clone specific for the Pigeon Cytochrome c (PCC) peptide 81- 104. Cells were maintained
by stimulating 4x10 cells for 48 hours with 8 /-M whole PCC and 40x10 irradiated
(3000 rad) syngeneic (BlO.BR) splenocytes in 8 ml complete media (50% RPMI/50%
EHA cell cultue media, 10% Fetal Bovine Serum (FBS), 100 units/ml penicilin, 100
/-g/ml streptomycin, 2 mM L-glutamine, 55 /-M -mercaptoethanol) in a 6-well plate.
The cells were then expanded l:20 into 152 ml fresh media with 15 U/ml rmL-2. After a
minimum of 12 days, when the IL-2 was consumed and the cells were rested, live cells
were isolated on a ficoll gradient (Lympholyte M, Accurate Chemical & Scientific Corp.
Westbur, NY) and utilized for anergy induction.
EL-4 is a mouse thymoma T cell line maintained between 0.05-2x10 cells/ml in
complete media (RPMI cell cultue media, 10% Fetal Clone , 100 unitslml penicilin, lOO
/-g/ml streptomycin, 2 mM L-glutamie, 55 /-M -mercaptoethanol).
JT Ag cells are Jurkat human leukemic T cells transfected with the large T cell
antigen (TAg), resulting in the maintenance of transiently transfected plasmids containing
the SV40 origin of replication in high copy number. This cell line (a gift from L. Berg,
UMASS , Worcester, MA) was maintained between 0.05-2x10 cells/ml in complete
media (RPMI cell cultue media, 10% Fetal Clone, 100 unts/ml penicilin, 100 J.g/ml
streptomycin, 2 mM L-glutamine, 55 J.M -mercaptoethanol).
Induction of anergy
Live A.E7 T cells were isolated over a ficoll gradient (Lympholyte M, Accurate
Chemical & Scientific Corp. , Westbury, NY) by centrfuging 100-250x10 cells in 12.
ml of 1 % FBS culture media over 7 ml ficoll at 1300xg, 22 , 20 min. The cells were
washed 3 times, resuspended in 10% FBS culture media, and counted by trpan blue
exclusion. Either 20-40xl06 cells or lOOx10 cells at lxl06/ml were stimulated in a T75
or T175 tissue culhre flask, respectively (BD Falcon, Bedford, MA) previously coated
with anti-CD3 monoclonal antibody (mAb) (clone 145-2Cll) (BD Biosciences
Pharmingen, San Diego, CA) at a concentration of J.g/ml in PBS at 37 C for 1-2 hours.
After incubation with antibody, the flasks were washed 3 times with PBS before cells
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were added. Activated control cells were incubated under the same conditions with the
addition of soluble anti-CD28 mAb (clone 37 .5l) (BD Biosciences, Pharmingen, San
Diego, CA) at J.g/ml. Mock-stimulated control cells were incubated in a flask coated
with isotype control IgG antibody (BD Biosciences, Pharingen, San Diego, CA) under
the same conditions in the absence of soluble antibody. After overnight incubation, flasks
were placed on ice, the cells were scraped, washed 3 times with 1 % FBS culture media
and processed for RNA, protein, or rested for a varable amount of time in 10% FBS
cultue media.
Proliferation assay
Anergized or control cells that had been resting for at least 5 days (unless
otherwise specified) were counted and resuspended in 10% FBS cultue media. Twenty
thousand cells were coincubated with 0.5x10 irradiated (3000 rad) syngeneic spleen cells
and increasing doses of whole PCC in a total of 200 f.l in a 96-well plate in trplicate. As
a control , cells were incubated with IL-2 at 10- 15 U/ml instead of antigen. Cells were
stimulated for 64-70 hours and were pulsed with 1 f.Ci eH)-thymidine for the last 16
hours of cultue.
IL-2 ELISA
Cells were stimulated in a 96-well plate as above for 14 hours. Instead ofIL-2 as
a control, cells were incubated in the presence ofPMA (75 ng/ml) and Ionomycin (1
f.g/ml) (Sigma-Aldrch, St. Louis, MO). The supernatant was then removed and stored at
C until analyzed. Ninetysix-well plates were coated overnight with 100 f.l anti-IL-
capture antibody (clone JES6- 1AI2) (BD Biosciences, Pharmingen, San Diego, CA) at a
dilution of 1:500 in coating buffer (O. lM Carbonate Buffer, pH 9.5) and then washed
with PBS- Tween-20 (0.05%). One hundred- fift microliters recombinant mouse IL-
(R&D Systems, Mineapolis, MN) standards (8- 500 pg/ml) or supernatants were added
to the coated plates and incubated for 1 hour at room temperatue. Plates were washed
with PBS- Tween-20 and then 100 f.l biotinylated anti-IL-2 detection antibody (clone
JES6- 5H4)(BD Biosciences, Pharingen, San Diego, CA)(1 :500) was added for 1 hour
at RT. The plates were washed with PBS- Tween-20 followed by incubation with 100 p,l
horseradish peroxidase-avidin D (Vector Laboratories , Inc. , Burlingame, CA) (1 :2500) in
PBS- Tween-20 at RT for 20 miutes. The plates were washed in PBS- Tween-20
followed by PBS, and incubated with 100 p,l OPD buffer (50mM Na2HP04, 25mM
NaCitrate, pH 5.0) with peroxide added until color developed. The reaction was stopped
by adding 25 p,l3M HCl. The plates were then read at a wavelength of 490 nm in a
Maxline microplate reader (Molecular Devices Corp. , Sunyvale, CA).
Microarray procedures
A.E7 T cells that had been pretreated (mock-stimulated, anergized, or activated)
as described and rested for 0 2 or 5 days were processed for total RNA (RNeasy, Qiagen
Valencia, CA) according to the manufactuer s instrctions. Fifteen micrograms of total
RNA per sample was reverse-transcribed into double stranded-cDNA with tre TI-(dT)24
pnmer (5'
GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG-(dT)24- ) using the
SuperScript Choice system (Gibco BRL Life Technologies, Rockvile, MD) according to
manufactuer s instrctions. cDNA was cleaned up by extraction with (25:24:1)
phenol:choloroform:isoamyl alcohol (Ambion, Austin, TX) followed by centrfugation
over a Phase Lock Gel (Eppendorf.5 Prime, Inc. , Boulder, CO). cDNA was then
precipitated with 0.5 volumes of7.5M NH4Ac and 2.5 volumes of cold absolute ethanol
washed twice with 80% ethanol, and resuspended in l2 p,l of RNase- free water. Five
microliters of cDNA was then used as a template for the in vitro transcription of
biotinylated cRNA using the BioAray High Yield RNA Transcript Labeling Kit (Enzo
Life Sciences Inc. , Faringdale, NY) according to manufactuer s instrctions.
Biotinylated cRNA was isolated using an RNeasy Min colum (Qiagen, Valencia, CA),
eluted with water, and quantified by spectrophotometer at ODz60. Sixty micrograms 
biotinylated cRNA was fragmented in fragmentation buffer (200mM Tris-acetate, pH 8.
500mM KOAc, 150mM MgOAc) at 94 C for 35 minutes at a fmal concentration of 0.
j.g/j.l. Fifty- five micrograms of fragmented cRNA was added to the hybridization
cocktail (0.05 ug/ul fragmented cRNA, 50 pM Control Oligonucleotide B2 (Affymetrix
Santa Clara, CA), Eukaryotic Hybridization Controls BioB, BioC, BioD, cre (Affymetrx
Santa Clara, CA), 1.5 , and 100 pM, respectively, 0. 1 mg/mL Herrng sperm DNA
(PromegaiFisher Scientific, Madison, WI), 0.5 mg/mL acetylated BSA (Gibco BRL Life
Technologies, Rockvile, MD), IX Hybridization Cocktail (lOOmM MES , 1M (Nal,
20mM EDTA, O.Ol % Tween 20)). Fresh cocktail was prepared and hybridized to each 
the mgU74v2 A, B , and C chips (Affymetrx, Santa Clara, CA) in the microarray core
facility at the University of Massachusetts according to standard protocol.
Quantitative R /PCR
Total RNA was prepared using an RNeasy kit (Qiagen, Valencia, CA) according
to manufactuer s instrctions. cDNA was synthesized using oligo-dT primers and
reverse transcriptase AMV (Roche, Indianapolis, IN) according to manufacturer
instrctions. Quantitative rea time PCR was performed in a Light Cycler (Roche
Indianapolis , IN) using a SYBR Green I PCR kit (Roche, Indianapolis, IN) and specific
primers to amplify 200- 1000 bp fragments from the different genes analyzed. A standard
cure was generated for each run with total RNA from an unstimulated or a 24-hour
ConA-stimulated mouse spleen cell preparation and used as a reference to calculate
relative units of expression for each gene in each sample. Melting curves and gel
electrophoresis confirmed the purty of the amplified band. Normalization was achieved
by includig samples with priers for HPRT.
Primer sequences for the genes analyzed are as follows: HPRT (f) 5'
ttagcgatgatgaaccaggtat-3' (r) 5' - tggcctgtatccaacacttc- Pac- (f) 5'
ggaaatcttgccctacctgtacttg-3' (r) 5'
-accatatcagagcagccgtcat- Bace- (f) 5'
ggaagctgtggcacgaacatct-3' (r) 5' -catcacggtcgcaccaatcac- AKOll178 (f) 5'
ccggccactgaacgagatg-3' (r) 5' ggaaggcccaaacataagga- Osteopontin (f) 5'
ccgaggtgatagcttggcttatg (r) 5' -ctgcccttccgttgtgt- Egr- (f) 5' -agtgcacgaaaggccctatc-
IL- (f) 5'-caacagcgcacccacttc-3' (r) 5' -cgaattggcactcaaatgtgt-
Western blotting
At indicated times, cells were washed once in PBS, resuspended in SDS gel
loading buffer without bromophenol blue or 
- mercaptoethanol, and boiled for 5-
minutes. Protein concentration was then determined using the BCA protein quantification
assay (Pierce, Rockford, IL). Bromophenol blue and 
-mercaptoethanol were added to
the samples and equal amounts of protein were loaded on a 10% SDS protein gel.
Samples were ru at 150 volts for 30-60 minutes and then transferred to PVDF
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membrane at 100 volts for 1 hour. For phospho-ERK and total ERK blots, the membrane
was blocked in blocking buffer (TBS- tween-20 (0.05%) with 5% BSA for total ERK, 5%
Blotto (Sigma-Aldrich, St. Louis , MO) for all others) for 1 hour at RT. The blots were
then probed with anti-phospho-ERK (Cell Signaling, Beverly, MA) (l:1000) or anti-ERK
(Cell Signaling, Beverly, MA) (1: 1000) in blocking buffer at 4 C overnight. For all
others, blots were blocked overnght (5% Blotto) at 4 C and then probed with anti-Egr-
(Covance , Richmond, CA) (l:200), anti-Egr- l (Santa Cru Biotechnology, Santa Cru
CA) (1:1000) or anti-B-actin (Sigma-Aldrch, St. Louis, MO)(1:50 000) in blocking
buffer (5% Blotto) at RT for 1 hour. After incubation with primary antibody, the
membrane was washed with TBS- Tween-20 and probed with secondary goat anti-rabbit
antibody conjugated to horseradish peroxidase (Chemicon Int. , Temecula, CA)
(1:10 000) or goat-anti mouse (Chemicon Int. , Temecula, CA.) (1:10 000) in blocking
buffer (5% Blotto) for 45 minutes. The membrane was washed with TBS-Tween-20
followed by a wash in TBS , developed in chemiluminescence (perki Elmer, Boston
MA) (most blots) or enhanced chemilumnescence (Pierce, Rockford, IL) (phospho-
ERK) and exposed to Kodak X-OMAT AR film.
Flow cytometry
For extracellular staining, cells were washed in F ACS buffer and incubated with
10 III anti-CD4 mAb-APC (1:25), anti-CD4 mAb-PerCP-Cy5. 5 (1:20), anti-CD25 mAb-
APC (1:40), and/or anti-CD8 mAb-PerCP-Cy5.5 (1:10) (BD Biosciences, Pharmingen
San Diego, CA) diluted in F ACS buffer (O. l % NaAzide, 0. 1 % BSA in PBS) on ice for 30
minutes. For intracellular staining, cells were washed once in PBS , stained with
Live/Dead Blue viability marker (Molecular Probes Inc. , Eugene, OR) according to
manufactuer s instructions , washed in PBS, and fixed on ice in 200f.l3% formaldehyde
for 30 min. Cells were then washed in Stainig Buffer (SB) (3% Fetal Clone , 0. 1 %
NaAide in PBS) and permeablized at room temperatue in 100 ul 0.5% Triton X- IOO in
PBS for 10 min. Next, cells were washed with SB and blocked at room temperatue in 45
f.lBlockig Buffer (BB) (5% Fetal Clone, O.1M Tris pH 7. , 0.01% Triton X- 100) for 10
miutes. Five microliters of anti Egr-2 (Covance, Richmond, CA )(1 :20 in BB) or anti
Egr- l antibody (Santa Cru Biotechnology, Santa Cruz, CA) (1:40 in BB) was added to
the block (1:200 or 1:400 final dilution, respectively) and incubated at room temperature
for 30 minutes. Cells were then washed in SB and incubated with 50 f.l anti-rabbit
secondary F(ab' )2 antibody fragment conjugated to FITC (1:200) or PE (1:50) (Jackson
Immunoresearch Laboratories, Inc. , West Grove, PA) in BB at room temperatue for 30
minutes. Cells were washed in F ACS buffer, resu;pended in 1 % paraformaldehyde in
F ACS buffer, and kept at 4 C until data was collected on an LSRII flow cytometer (BD
Biosciences, San Jose, CA) using DigiF ACS softare (BD Biosciences, San Jose , CA).
Post-acquisition analysis was performed with FlowJo softare (Treestar, San Carlos
CA).
,,,
CFSE labeling
Cells were washed and approximately 3xl06 were resuspended in 0.5 ml PBS. An
equal volume of 1 /lM CFDA SE (carboxyfluorescein diacetate succinimidyl ester
Molecular Probes Inc. , Eugene, OR) in PBS was added (final concentration of 0.5 /lM).
Cells were mixed and incubated at R T for 3 minutes. Labeling was quenched by addition
of an equal volume of FBS , cells were washed twice in PBS , resuspended in complete
medium and total number of cells determined by tran blue exclusion. One-half milion
cells were added to 2.5x10 syngeneic (B1O.BR) splenocytes with or without lO /lM PCC
in a total volume of 1 m1 complete media in a 48-well plate and incubated for 4 days.
Cells were then stained with Live/Dead Blue fluorescence (Molecular Probes Inc.
Eugene, OR) according to manufactuer s instructions and at least 10 000 live events
were collected on an LSRII flow cytometer (BD Biosciences , San Jose, CA) using
DigiFACS softare (BD Biosciences). Post-acquisition analysis was performed with
FlowJo softare (Treestar, San Carlos, CA).
Cloning of pfosB- Luc reporter plasmid
Approximately 1.5 kb of sequence upstream of the fosB transcription start site
(portion of the promoter containing Egr-2 binding sites) was PCR-amplified using the
following primers: forward) 5' -actgtgctagccccggaaaagccacctatcct-3' (reverse) 5'
actgtctcgagtcagaccgccgctgtacct- 3' . Each prier contains an enzme restrction site 5' to
the anealing portion. The PCR product was digested with NheI and XhoI and cloned
ili/
into the same sites in the vector pGL3 , a promoterless Luciferase expression plasmid
(Promega, Madison, WI). A successful constrct was identified by enzyme restriction
verified by sequencing, and tested for inducibility by PMA and Ionomycin in a transient
transfection luciferase assay.
Transient transfection
EL-4 thymoma or JTAg cells were electroporated with 15 Ilg pIL2-Luc (a
generous gift from L. Berg, University of Massachusetts Medical School, Massachusetts)
or 5 Ilg pfosB-Luc (cloned as described) or pjunB-Luc (JB2 , B. Eggen, University of
Groningen, Netherlands), 21lg pRL TK (Promega, Madison, WI), and increasing
amounts ofCMV-HA-Egr-2 expression plasmid (pJDMl118 , a kind gift from 1.
Milbrandt, WUMS , St. Louis , MO) or control pCMV5 plasmid in complete media at
20x10 /ml in 0.5 ml in a 0.4 cm cuvette (BioRad) at 320 volts, 950 uFo The cells were
incubated on ice 10 minutes and then added to 5 ml complete media in a 6 well plate to
recover for at least 6 hours.
Stable transfection of EL- 4 thymoma cell line 
Fort million EL-4 thymoma cells were electroporated as above with 20 Ilg of
CMV-HA-Egr2 expression plasmid pJDMll18(above) or control plasmid pJDMll18(-),
in which the coding sequence of Egr-2 was removed by restriction digestion with BamI
and BglI and the vector re- ligated. Ten millon electroporated cells were plated per 24
well plate at 1 ml/wel1. Electroporated cells were allowed to recover for 24 hours
(approximately 2 doublings) after which G418 (Genetic in, GibcoBRL/Invitrogen Life
Sciences , Carlsbad, CA)(400 Ilg/ml) was added to the cultues. Cells growing out 3-
weeks later were expanded, frozen, and tested for Egr-2 expression by western blotting
with anti-Egr2 antibody.
Luciferase assay
Transiently transfected cells were stimulated with PMA (75 nglml) and
Ionomycin (illg/ml) (Sigma-Aldrch, St. Louis, MO ) for 12 hours (IL-2 promoter) or 3
hours (fosB andjun promoters). Cells were then harvested, washed once in PBS , lysed
with 50 III IX PLB (Promega, Madison, WI) at room temperatue l5 minutes , spun at
max speed in a microcentrfuge at 4 C for 2 minutes, and supernatants transferred to
another tube. Twenty microliters of each lysate was analyzed using the Dual Luciferase
Assay Kit (Promega, Madison, WI) according to manufactuer s instrctions.
Electroporation of A.E7 with siRNA
Two separate, nonoverlapping Egr-2-specific siRNAs (Dharacon, Lafayette
CO) were determined to effectively silence Egr-2 expression in anergic cells. The
sequences are as follows: Egr2-7) gugaccaccuuacuacucadtdt (sense),
ugaguaguaagguggucacdtdt (anti- sense) and Egr2- 8) guuugccaggagugacgaadtdt (sense),
uucgucacuccuggcaaacdtdt (anti-sense). An irrelevant siRNA was synthesized as control
with the following sequence: con) cagucgcguuugcgacuggdtdt, ccagucgcaaacgcgacugdtdt.
Anergic or resting A.E7 T cells were electroporated with 2 , 5 , or 20 nmoles of siRNA
duplex in 0.5 ml complete growth medium at a density of60 x l06/ml in a 0.4 cm
GenePulser cuvette (BioRad, Hercules, CA). The electroporation was performed with a
GenePulser electroporator II (BioRad, Hercules , CA) at 310 mY, 950 IlF. Cells were
allowed to recover for 10 minutes on ice and then added to complete growth medium.
Cells transfected prior to anergy induction were rested for 4-6 hours at 37 C before being
anergized.
Cell stimulation for ERK horvlation
Five milion resting or anergic cells, with or without siRNA as indicated, were
stimulated with immobilized anti-CD3 mAb (clone 145-2Cll) (BD Biosciences
Pharingen, San Diego, CA) precoated at Ilg/ml and soluble anti-CD28 mAb (clone
37.51) (BD Biosciences, Pharingen, San Diego, CA) at Illg/ml in a 6-well tissue
culture plate (BD Falcon, Bedford, MA) in 1 ml of media. Immediately after addition of
the cells, the plate was centrfuged at 300xg for rapid contact and incubated at 37 C for
60 miutes. After the incubation, cells were removed from the stimulus and protein was
isolated for western blotting.
Results
Establishment of A.E7 anergy model
I first established the well-studied in vitro model of T cell clonal anergy
developed in the laboratory of R. Schwarz (17). A.E7 T cells were anergized by
incubating overnight with platebound anti-CD3 monoclonal antibody (mAb). Non-
anergized controls included 1) mock-stimulated A.E7s incubated with platebound IgG
control antibody and 2) activated A.E7s incubated with plate bound anti-CD3 mAb plus
soluble anti-CD28 mAb. After the indicated rest period, these populations were
rechallenged with irradiated syngeneic antigen presenting cells (APC' s) plus pigeon
cytochrome c (PCC) antigen to assess their levels of responsiveness. Stimulated cells
were either pulsed with trtiated thymidine to measure proliferation (Figure 7a) or the
supernatats of the cells were harvested and assayed for IL-2 production (Figure 7b). I
determined that 5 days of rest after removal from the stimulus was the earliest time at
which cells could be identified as anergic, i.e. the anergic cells were hyporesponsive
while the activated control cells were responsive to antigen rechallenge. At earlier
periods, activated controls were equally unesponsive to rechallenge as anergic cells.
Whle activated control cells are responsive to antigen at high doses and appear to
respond to the same extent as mock-stimulated control cells after a suffcient rest period
at low antigen dose they are hyporesponsive, similar to anergic cells.
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Legend to Figure 7: Following at least 5 days ofrest, an anergizing stimulus of A.E7 T
cells results in hyporesponsiveness to antigen rechallenge while activated and mock-
stimulated cells are responsive. A.E7 T cells were exposed to platebound anti-CD3 mAb
(anergized and activated) or platebound IgG antibody (mock-stimulated control)
overnight. Activated cells received an additional stimulus of soluble anti-CD28 mAb.
The three populations were then submitted to secondar challenge with antigen-pulsed
APC' s after 3 , or 7 days ofrest. Level ofresponsiveness to secondar challenge was
assessed by (A) trtiated thymidine incorporation into DNA or (B) IL- secretion.
- -- - - --- -.
Microarray analysis
I hypothesized that the hyporesponsive state demonstrated to be a hallmark of T
cell clonal anergy was due to expression of key genes in anergic cells. In addition, I felt it
probable that the expression profie responsible for anergy involved more than one , and
likely many, genes. I felt that the best, unbiased approach to characterizing the anergic
expression profile would be a large-scale screen using microaray technology.
In order to identify key players in both the induction and maintenance of anergy, I
decided to look at expression profies at three times-durg early, middle and late
phases of anergy. The first timepoint was the earliest the cells could be processed for
RNA isolation, imediately following l2 hours of stimulation (12 hours). In order to
avoid confounding effects of mock-stimulated control cells undergoing apoptosis after
prolonged rest, the latest time was the earliest at which the anergic phenotye could 
reliably demonstrated, i.e. the activated control cells were responsive while the anergic
cells remained unesponsive , which was 5 days following removal from the stimulus (rest
day 5). The middle time was 2 days following removal from the stimulus (rest day 2)
because it was a time when the activated control cells exhbited a high level 
proliferation while anergic cells remained quiescent. These selected timepoints represent
a period prior to, durg, and after proliferation in the activated control population.
We decided that each timepoint was best assessed in trplicate and so 27 samples
(3 populations, 3 timepoints, 3 replicates) were processed for total RNA and prepared for
hybridization to the mouse genome U74 version 2 series GeneChips from Affyetrx.
The mgU74v2 array series consists of3 individual chips, each representing -12 000
expressed sequences , with known genes represented on chip A, and unown expressed
sequence tags (EST's) represented on chips Band C. I performed each replicate and each
timepoint as a separate experient and the samples were prepared and hybridized as soon
as they became available. Since the mgU74v2 series consisted of 000 expressed
sequences arrayed onto 3 different chips (A, B , and C), I chose to process enough RNA
from each experiment to produce a separate hybridization cocktail for each chip, rather
than 1 hybridization cocktail per sample and hybridizing it to all 3 chips sequentially as
recommended by the manufacturer. This can result in decreased signal after each
hybridization, with loss of information for low-expression genes (F. He, Jacobson Lab
UMASS Medical School, unpublished results).
In analyzing the micro aray data, I chose to identify genes that were up- or
downregulated at least 1.7 fold in anergic cells compared to both mock-stimulated and
activated controls. This low-strngency requirement was used by others (60), and was
likely to identify a large number of genes that could later be restrcted if desired. I also
required that candidates appear differentially expressed in each of the 3 replicate
experients, and in the same direction in all of the experiments, i.e. if the gene was
upregulated in anergic cells, it must be upre gulated in all 3 replicates.
At the earliest timepoint, 12 hours, IL-2 was differentially expressed between
anergic and mock-stimulated control cells, as well as between anergic and activated
control cells (Figue 8a). These results were confirmed by quantitative RT-PCR (qRT-
PCR) using the RNA from one of the micro array experients (Figue 8b). Aside from
IL- , only 1 other gene fulfilled the criteria; Granzme B is upregulated to a greater
'7,
extent in anergic cells at this early timepoint, but is not expressed on days 2 and 5 (Figure
8c).
At the middle timepoint, rest day 2 , a large cohort of genes are differentially
expressed in anergic cells compared to controls. Because this is a time when the activated
control cells are proliferating and anergized cells are blasting (but remain undivided), it is
not surrising that widely varing expression profies were observed. Because of the
large number of differentially expressed genes at this time, it is particularly diffcult to
identify interesting candidates to pursue. Therefore , candidates that are only differentially
expressed at day 2 wil not be fuher discussed.
Because genes continuing to be differentially regulated on rest day 5 are most
likely to playa direct role in the anergic phenotye, these candilates were analyzed
fuher, and the expression levels at all times are reported. I gave particular attention to
genes that were induced at 12 hours (prior to proliferation) in both anergic and activated
cells, downegulated after proliferation in the activated population, and stil present in
anergic cells on day 5. This is the pattern of expression predicted of an "anergic factor" in
the study by Powell et al. (25). On rest day 5 , a small number of genes are differentially
expressed accordig to the above requirements. Two ESTs have an interesting expression
profie. AI152789 is upregulated early in both anergic and activated cells, becoming
differentially expressed in anergic cells primarily on day 2 but also day 5 (Figure 9a). The
other, AKOlll78 , is not fully expressed until day 2 and remains at increased levels in
anergic cells through day 5 (Figure 9b). Quantitative RT-PCR confirmed the observed
expression profie of AKO 11178 (Figure 9c). Osteopontin, a secreted cytokine first
identified in bone matrx, is expressed early in both anergic and activated cells but is
differentially expressed on rest days 2 and 5 , downegulated more quickly in the activated
population (Figure lOa). Beta-APP cleaving enzyme 2 (Bace-2) is a membrane protein
with secretase activity that is expressed only on days 2 and 5 in anergic cells and, to a
much lesser extent, activated cells (Figue lOb). Phosphatase of activated cells- l (Pac-
is an ERK phosphatase that is differentially expressed according to the requirements in
only 2 of the 3 experients but is wo rth reporting here. Its expression is increased in
anergic cells on day 5 only, narowly missing the 1.7 fold upregulation requirement in
one replicate (Figure 10c). The expression profies of these genes were confirmed by
qRT-PCR (Figue IOd-f).
Egr- , a zic- fmger transcription factor, is upregulated at l2hr in both anergic and
activated cells and is not expressed in mock-stimulated controls. It is present at high
levels only in anergic cells on rest days 2 and 5 (Figue lla). It should be noted that
although expression levels of Egr-2 reported as "average difference" do not appear to
show differential expression in the 3rd day 5 replicate experiment, the analysis softare
reports a 3- fold upregulation in anergic cells compared to activated cells and a 6- fold
upregulation over mock-stimulated cells. This discrepancy is due to an error in the
algorithm utilized by the analysis softare. The observed pattern of expression on the
GeneChip was confirmed by qRT-PCR analysis of the transcript (Figure lIb).
1jt
20000
IL-
15000
10000
5000
.m....__m .. '" -",- "... m................' "...n...
_" '-"'-"
mm"'_'_"m'H'_H"
'--"'''''''
IL-
8000
g 6000
(5 4000
2000
Figure 8
Granzyme B
Legend to Figure 8: Analysis of mRNA profiles immediately following 12 hours of
mock- , anergizing, or activating stimuli. A.E7 T cells were exposed to platebound IgG, a
control mock-stimulus (C), to platebound anti-CD3 mAb, an anergizing stimulus (A), or
platebound anti-CD3 plus soluble anti-CD28 , an activating stimulus (S) for 12 hours.
Total RNA was isolated, processed into cRNA, and hybridized to Affyetrx GeneChips
or used directly for qRT-PCR. GeneChip signal is reported as the average signal
difference between the gene probe and a nonspecific control. All 3 replicates are shown
(R1-3). The qRT-PCR signal is reported relative to HPRT. (A) GeneChip analysis shows
that IL-2 is not present in mock-stimulated control cells and is upregulated slightly
following an anergizing stimulus, but to a much greater extent following a full , activating
stimulus (6- fold higher). (B) qRT- PCR confirms this observation. (C) Granze B is not
present in mock-stimulated cells but is greatly induced in anergic cells. It is induced to a
smaller extent in activated cells.
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Legend to Figure 9: Identification of expressed sequence tags (ESTs) differentially
expressed in anergic cells after 5 days of rest. A.E7 T cells were treated as in Figue 8
(mock-stimulated (C), anergized (A), activated (S)) and processed immediately for RNA
(l2 hr) or rested 2 days (Day 2) or 5 days (Day 5) before RNA isolation. Total RNA was
processed and analyzed by GeneChip or qRT-PCR as in Figue 8. The criteria required
for genes to be reported include differential expression on day 5. Expression profies are
reported for all 3 replicates (Rl-3) at all 3 times. (A) The EST AI152789 is induced by l2
hours in both anergized and activated cells but remains elevated in only anergic cells at
day 2 , and to a lesser extent at day 5. (B) The EST AKO 11178 is not significantly
expressed until rest day 2 , at which point it is expressed at highest levels in anergic cells.
This differential expression is maintained on rest day 5 , but the expression is lower than
on rest day 2. (C) qRT-PCR confirms the GeneChip results for AKOlll78.
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Legend to Figure 10: Identification of known genes differentially expressed in anergic
cells after 5 days of rest. A.E7 T cells were treated as in Figure 8 (mock-stimulated (C),
anergized (A), activated (S)) and processed imediately for RNA (12 hr) or rested 2 days
(Day 2) or 5 days (Day 5) before RNA isolation. Total RNA was processed and analyzed
by GeneChip or qRT-PCR as in Figure 8. The criteria required for genes to be reported
include differential expression on day 5. Expression profiles are reported for all 3
replicates (Rl-3) at all 3 times. (A) Osteopontin is induced to similar levels following a
l2- hour anergizing or activating stimulus. Differential expression is more evident in
anergic cells after 2 days of rest. It is stil expressed in anergic cells at low levels after 5
days and to a lesser extent in activated cells. (B) Bace-2 is not expressed after 12 hours of
anergizing or activating stimulus. It is highly expressed after 2 days in anergic cells and
at this time , is upregulated in anergic compared to activated cells. Differential expression
is maintained on day 5. (C) Pac- l expression, while highly varable in the samples, is
only differentially expressed on day 5. (D,E) qRT-PCR confirms the GeneChip data for
Osteopontin and Bace-2 expression. (F) qRT-PCR analysis ofPac- l expression is as
varable as the GeneChip data, and only one of two replicates on day 5 shows increased
expression in anergic cells.
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Legend to Figure 11: Egr-2 expression in mock-stimulated, anergic , and activated cells.
A.E7 T cells were treated as in Figue 8 (mock-stimulated (C), anergized (A), activated
(S)) and processed immediately for RNA (12 hr) or rested 2 days (Day 2) or 5 days (Day
5) before RNA isolation. Total RNA was processed and analyzed by GeneChip or qRT-
PCR as in Figure 8. Expression profiles are reported for all 3 replicates (Rl-3) at all 3
times. (A) Egr-2 expression is increased in both anergic and activated cells following 12
hours of stimulation but remains at an elevated level only in anergic cells on days 2 and
5. The third replicate on day 5 appears not to show differential expression; however, this
is due to an error in the algorithm used by the GeneChip analysis softare. (B) qRT-PCR
confIrms the GeneChip results.
Egr-2 protein levels correlate with anergy
I analyzed Egr-2 protein levels in anergic and control A.E7 T cells over 9 days by
western blot (Figue l2a). Egr- , while not expressed in mock-stimulated T cells, is
upregulated equally in anergic and activated control cells after 12 hours of stimulation.
Over the following days, Egr-2 is diminished in activated cells compared to anergic cells.
By day 5 , coinciding with the earliest day when activated control cells are responsive to
antigen rechallenge, protein levels are essentially at resting levels in this population.
Interestingly, the rapid downegulation of Egr-2 protein level in activated cells between
rest days 3-5 coincides with the greatest increase in cell number at that time, reflecting
proliferation of these cells (Figue 12b). The cells were stimulated on rest day 9 to assess
responsiveness to antigen rechallenge (Figue l2c).
Because the addition of exogenous IL-2 induces proliferation in anergic cells and
abrogates the anergic phenotye, I assessed protein levels of Egr- 2 in anergic cells 
, and lO days following exposure to IL-2 (Figue l2d). The cells were stimulated on rest
day 10 to assess responsiveness to antigen rechallenge (Figue l2e). Simlar to
proliferating cells following activation, proliferating anergic cells exposed to IL-2
downeguate Egr-2 protein and are more responsive to stimulation than anergic cells not
exposed to IL-2.
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Legend to Figure 12: Egr-2 protein levels correlate regatively with proliferation and
with responsiveness to antigen rechallenge. A) Egr-2 protein levels were assessed by
western blot in cells that were mock-stimulated (C), anergized (A), or activated (S) as in
Figure 8. Cells were processed imediately after removal from stimulus (12 hr), and
after 1 , and 9 days of rest (Dl-9) in media. B) Live cells were counted by trpan
blue exclusion after 1 , 7 , and 9 days ofrest for comparison of Egr-
2 protein levels to
proliferation (increase in cell number). Proliferation is reported as a ratio of the cell
number on the indicated day to the cell number on day 1. C) After 9 days of rest
, the cells
were submitted to antigen rechallenge to assess responsiveness by eH)-thymidine
incorporation into DNA. D) Egr-2 protein is downregulated in anergic cells treated with
exogenous IL-2. Egr-2 protein levels were assessed by western blot in cells that were
mock stimulated (C) or anergized (A) as above. Cells were processed immediately after
removal from stimulus (12 hr), and after 1 , 3, , and 10 days of rest (Dl-
1O) in either
media alone or with exogenous IL-2 (10 unts/ml) to induce proliferatio and break
anergy. E) After 10 days of rest, the populations were submitted to antigen rechallenge to
assess level of responsiveness by tritiated thymidine incorporation.
Kinetics of Egr-2 and Egr- l upregulation following
stimulation
Following 6 days of rest, I submitted mock-stimulated, anergic, and activated
populations to secondar stimulation with platebound anti-CD3 mAb and soluble anti-
CD28 mAb for 0, 4 , and 12 hours and analyzed the Egr- l and Egr-2 protein level by
western blot. Whle Egr-2 is only expressed in anergic cells prior to stimulation, it is
quickly induced in all cell populations following stimulation (Figue 13a). Egr- l is not
expressed in any of the populations prior to stimulation but is upregulated quickly
following stimulation. However, in anergic cells, Egr- l is not upregulated to the same
extent as in previously mock-stimulated cells. This ' blunted" upregulation in anergic
cells is also observed to some extent in the previously activated, or "partially anergic
population (Figue 13b).
In order to determne the kinetics ofEgr- l and Egr-2 protein expression in A.E7s
stimulated in a more physiological way, I mixed previously mock-stimulated, anergic
and activated cells with T cell-depleted APC' s that had been loaded with a high (lOuM)
or low (0.3uM) concentration of PCC for 0, 3 , or 6 hours. Cells were then harvested
permeablized and stained for Egr- l or Egr-2 for analysis by flow cytometr. As was
determined by western blot, before stimulation (Ohr) Egr-2 is most highly expressed in
anergic cells (Figue l4a) while Egr- l is not expressed by any of the three populations
(Figue l4b).
Egr-2 is upregulated to maximal levels in previously mock-stimulated and
activated cells by 3 hours and remains at high levels for at least 6 hours. In anergic cells
Egr-2 begins at increased levels but is fuher induced to maximal levels with stimulation
after 3 hours (Figue l4a). Egr- l is also upregulated to maximal levels in previously
mock-stimulated cells by 3 hours but begins to retu to low levels after 6 hours. A high
antigen dose results in a more rapid upregulation of Egr- l than a low dose. In agreement
with the western blot, anergic cells fail to upregulate Egr- l to levels of mock-stimulated
cells when stimulated with both low and high antigen concentrations. Also, in contrast to
previously mock-stimulated cells, expressed levels ofEgr- l in anergic and, to some
extent, previously activated cells quickly return to pre stimulated levels after peak
expression (Figure l4b).
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Legend to Figure 13: 
Western blotting ofEgr- l and Egr-2 protein levels in mock-
stimulated (C), anergized (A), and activated (S) cells following secondary antibody
stimulation. Cells were treated as in Figure 8 (mock-stimulated (C), anergized (A),
activated (S)), rested for 6 days, and submitted to secondar stimulation for 0, 4
, or 12
hours with platebound anti-CD3 and soluble anti-CD28 mAb. Protein levels of (A) Egr-
and (B) Egr- l were then analyzed by western blot. Blots were stripped and reprobed with
an antibody for -actin to control for protein loading.
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Legend to Figure 14: Flow cytometr analysis of Egr- l and Egr-2 protein levels in
mock-stimulated, anergized, and activated cells following antigen rechallenge. Cells were
treated as in Figure 8 , rested for 6 days, and submitted to antigen rechallenge for 0, 3 or 6
hours with 0.3 or 10 11M PCC antigen and T cell-depleted syngeneic APe's. Cells were
then intracellular stained for (A) Egr- 2 and (B) Egr- l and analyzed by flow cytometr.
Effect of transient Egr-2 overexpression on IL-2, fosB, and
junB promoters
Because one of the hallmarks of the anergic phenotye is defective expression of
IL- , I searched the IL-2 promoter as well as the promoters of known activators ofIL-2
transcription for potential Egr-2 binding sites. When promoters were unpublished, I did
this by searching the Celera genome database for each of the genes, identified the
transcription star site, and examined the upstream 2 kilobases using TESS transcription
search tool on the internet. I found that the promoters of IL-2, fosB , and jun all
contained putative Egr-2 binding sites.
I tested these promoters for susceptibility to Egr-2 repression by obtaining vectors
with the promoters cloned into fIrefly luciferase reporter plasmids. The JT Ag human T
cell line or EL-4 thymoma T cell line was transiently transfected with one of the three
reporter plasmids, a CMV-Egr-2 expression plasmid, and a TK-Renila Luciferase
plasmid for transfection control. Transfected cells were allowed to recover for at least 6
hours, stimulated with PMA + Ionomycin overnight (IL-2 promoter) or 3 hours (fos and
jun promoters), harvested, and assessed for Luciferase activitiy. None of the promoters
appeared to be sensitive to Egr-2 repression (data not shown).
Stable transfection ofCMV-Egr2 into EL-4 T cells
EL-4 thymoma T cells were stably transfected with a CMV-HA-Egr-2 expression
plasmid and selected via G4l8 drg selection. A number of stable clones grew out with
resistance to G4l8. However, only two clones appeared to produce detectable levels of
Egr-2 by western blot (Figue l5a). One ofthe clones, 5Cl , produced Egr-2 at tre
expected size. Another clone, 5D3 , produced Egr-2 at a size slightly larger than expected.
The clone 5C 1 grew at a much slower rate than the others. In order to assess if there were
any cell cycle defects in this clone, I analyzed 5Cl by PI staining compared to the faster-
growing controls. Strgly, there was a much higher proportion of dead cells in the 5Cl
compared to controls- l 1.5% versus 2. 2% (Figure l5b).
The clones were then tested for IL-2 production in response to antibody
stimulation. They were exposed to platebound anti-CD3 mAb and soluble anti-CD28
mAb for 20-24 hours when the supernatant was harvested for analysis by ELISA. There
was wide variability of IL-2 secretion among the clones. Interestingly, the clone 5D3
produced little to no IL-2 in response to antibody stimulation (Figue 15c), while
production in response to PMA and Ionomycin stimulation was copious (data not shown).
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Legend to Figure 15: Transfection of an Egr-2 expression vector in Elr4 thymoma cells
followed by G4l8 drg selection results in 2 stable clones expressing Egr-2; one with a
growth defect, one with an Ilr2 production defect. (A) Western blot of stable clones
overexpressing Egr-2. Clone 5Cl expresses Egr-2 at the expected size while 5D3 makes a
product that is larger than expected compared to Cos cells transiently transfected with the
vector (Egr-2). Control transfected cells (con) make no Egr-2. (B) PI staining ofElr4
stable clones shows cells in different stages of the cell cycle. The shar peak represents
cells in G 1 phase and cells with less staining (gate shown) represent dead cells. The slow-
growing 5C 1 clone has 11.5% cells within this gate compared to the other clones (2.
2%). (C) IL-2 production in stimulated EL-4 stable clones. Clones were stimulated with
increasing amounts of platebound anti-CD3 (0- 10 Ilg/ml) and soluble anti-CD28 mAb (1
Ilg/ml). Antibody labeling on the x-axis is represented as anti-CD3/anti-CD28 in Ilglml.
Supernatants were harested after 20-24 hours and analyzed for Ilr2 by ELISA.
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Anal sis of allotolerant mice bearin lon term skin
allo afts
In order to correlate the anergy phenotye with tolerance in vivo, long-term skin
allograft recipients were sacrificed and analyzed for the presence of Egr-2-expressing
CD4+ T cells. Ski graft recipients that had maintained skin allografts for at least 70
days, cohorts that were actively rejecting their grafts , or recipients of intact isografts were
sacrificed and either lymph nodes draing the graft or nodes irrelevant to the graft site
were collected for analysis by flow cytometr. Cells were extracted from the nodes
counted, and subsequently stained for flow cytometr for CD4, CD8 , CD25 , and
intracellular stained for Egr-2 or Egr- l (a control protein associated with activation but
not arergy). In general, there was little evidence for correlation of Egr-2 expression with
long-term tolerance of ski allografts when compared to rejecting or isograft controls. In
one experiment, however, 2 out of 3 mice with intact allografts had an increased
percentage of Egr-2 positive, CD4+ T cells in their draining lymph nodes when compared
to irrelevant nodes in the same mouse and to nodes draining isograft recipients (Figue
16). There was no correlation between Egr-2 and CD25 expression on CD4+ T cells in
any of the mice examined and, as expected, there was no increased expression of Egr- l in
tolerant mice (data not shown).
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Legend to Figure 16: Egr-2 expression by CD4+ T cells in lymph nodes draining a ski
allograft in mice tolerized by DST plus anti-CD40L. CD4+ T cells from the axilary
lymph nodes (ALN) draining a long- term (70- 80 days) graft oftolerized mice were
examed for Egr-2-expression by flow cytometry. Controls were pooled cervical nodes
(CLN) from the tolerant mice or axilar nodes from non-tolerant mice with isografts.
CD4+ cells were gated and analyzed as forward scatter vs. FITC (Egr-2 stainig). % Egr-
2 positive cells represent cells with staining increased over isotye control.
Egr-2 gene silencing using siRNA
In order to assess the role Egr-2 plays in the anergic phenotype, eight siRNA
oligos were designed from the mRA sequence of Egr-2. Each of the oligos was tested
for its ability to knock down Egr-2 protein levels in anergic A.E7 T cells. The cells were
anergized, rested for 5 days, and then electroporated with 20 nanomoles of each siRNA.
Protein levels were assessed by intracellular staining and flow cytometr 2 and 3 days
after treatment with siRNA (Figue 17). Two of the eight oligos (Egr2- 7 and Egr2-
were very effective in knockig down Egr-2 protein levels and were utilized for fuher
study.
Oligo Egr2- 7 was tested for its ability to knock down protein levels when
administered prior to anergy induction. A.E7 T cells were electroporated with media
alone or 20 nanomoles of control or Egr-2 siRNA. They were allowed to recover for 4-
hours and then anergized for 12 hours. Some cells were also electroporated with media
alone and left unstimulated as a non-anergic control. After 2 and 8 days of rest, cells were
stained for Egr-2 protein via intracellular staining and analyzed by flow cytometr
(Figue l8). While Egr-2 protein is stil induced to significant levels in anergized cells
treated with Egr-2 siRNA on rest day 2, protein is reduced in a population of cells to very
low levels after 8 days of rest when treated with Egr-2-specific siRNA. It appears that not
all cells are affected by siRNA knockdown, as there is a population (higher staining peak)
in the Egr-2 siRNA group that stil expresses Egr-2 at a high level. Note, in addition, that
even cells receiving no siRNA develop two staining populations of cells for Egr-2 (high
..'
and low). This was not observed in cells in which anergy was induced prior to siRNA
treatment.
Different quantities of siRNA were tested for the ability to knock down Egr-
protein levels when administered prior to anergy induction, with the intention of using the
lowest possible amount of siRNA. In one experiment, I compared 5 and 20 nanomoles
side by side; 5 nanomoles was suffcient for effective knockdown (Figue 19a). In a later
experiment, I compared 5 nanomoles to 2 nanomoles and, while I stil saw a significant
knockdown of protein using the lower amount (Figure 19b), I decided to use 5 nanomoles
for futue experiments.
In addition to flow cytometr, I chose to analyze Egr-2 protein knockdown by
western blot. When cells were removed for intracellular stainng by flow cytometry, they
were also processed for total cell protein. The mild effect of knockdown observed with
flow cytometr is contrasted with an apparently much more significant effect when
analyzed by western blot (Figue 19c.
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Legend to Figure 17: Eight siRNA duplexes (Egr2-(l-8)) designed from different
regions of Egr-2 mRA were tested for the ability to silence gene expression in anergic
E7 T cells. Twenty nanomoles of each siRNA was electroporated into anergic cells that
had rested for 5 days. Egr-2 protein level was assessed by flow cytometr 2 days after
siRNA treatment (rest day 7). The thin histogram in each box represents non-anergized
control cells (no Egr-2 expression). The dashed line represents cells treated with control
siRNA. The thick solid line represents cells treated with the indicated Egr-2-specific
siRNA. Duplexes Egr2- l through Egr2-4 were compared in one experiment and Egr2-
through Egr2- 8 were compared in another. Of the first 4 duplexes, Egr2-3 had the
greatest gene silencing effect. Of the last 4 duplexes, Egr2- , 7, and 8 all had an effect
and Egr2- 7 and 8 were the most effective.
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Legend to Figure 18: Gene silencing in cells transfected with siRNA before being
anergized. Cells were transfected with 5 nanomoles of siRNA and then anergized. Egr-
protein was analyzed by flow cytometr following 2 and 8 days of rest. The thin
histogram in each box represents non-anergized control cells (no Egr-2 expression). The
dashed line represents cells treated with control siRNA. The thick solid line represents
cells treated with Egr-2-specific siRNA. Very little Egr-2 gene silencing is evident after
only 2 days of rest following anergy induction. After 8 days, a population of cells
downegulates Egr-2 to low levels.
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Legend to Figure 19: Egr-2 gene silencing in cells treated with 20 , or 2 nanomoles of
siRNA. (A) Cells were transfected with 20 or 5 nanomoles of siRNA and then anergized.
Egr-2 protein was analyzed by flow cytometr after 5 days of rest. The thin histogram in
each box represents non-anergized control cells (no Egr-2 expression). The dashed line
represents cells treated with control siRNA. The thick solid line represents cells treated
with Egr-2-specific siRNA. Five nanomoles of siRNA is more effective at gene silencing
than 20 nanomoles. (B) Cells were transfected with 5 or 2 nanomoles of siRNA and then
anergized. Egr-2 protein was analyzed by flow cytometr after 5 days of rest. Five
nanomoles of siRNA demonstrates similar gene silencing to 2 nanomoles. (C) Cells
treated with 5 nanomoles of siRNA described in (B) were also analyzed for protein
expression by western blot after 2 , 5 , and 7 days of rest. The first lane, labeled "R" is
protein from resting cells that do not express Egr-2; all other lanes contain protein from
anergic cells electroporated with no siRNA (-), control siRNA (C) or Egr-2 siRNA (E).
The blot was then stripped and reprobed with antibody for -actin to control for protein
loading. After 5 and 7 days of rest, 5 nanomoles of siRNA was very effective at silencing
Egr-2 gene expression.
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Egr-2 is required for anergy induction
To determine the role of Egr-2 in anergy maintenance, anergic cells were
subjected to electroporation with Egr-2 siRNA after 5 days of rest. The cells were
analyzed for decreased expression 48 hours later (rest day 7) by flow cytometr and then
rechallenged to determne if Egr-2 played a direct role in maintaining
hyporesponsiveness in anergic cells. In a prelimiary experiment, knockdown ofEgr-
was significant but had no effect on the responsiveness to antigen rechallenge (rest day
12) of anergic cells when compared to cells transfected with a control duplex (Fige 20).
To determine the role of Egr-2 in anergy induction, A.E7 T cells were
electroporated with Egr-2-specific siRA, rested for 4-6 hours , and then anergized
overnght. A population of cells was electroporated and left unstimulated to serve as a
non-anergized control. Egr-2 protein levels were followed by flow cytometry (Figue
2la) and by western blot (Figure 2lb). As described above, Egr-2 protein was decreased
signficantly on rest days 5 and 7 in anergic cells receiving Egr-2-specific siRNA
compared to control. Cells were rechallenged on rest day 5 , 6 , or 7 and those with Egr-
knockdown consistently demonstrated a significant increase in responsiveness to antigen
rechallenge assessed by both trtiated thymidine incorporation (Figue 21c) and by
analysis of CFSE, a fluorescent marker that binds to cellular proteins and is diluted in
half with each cellular division (Figue 2ld).
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Legend to Figure 20: Egr-2 gene silencing after anergy induction has no effect on
responsiveness to antigen stimulation. In a preliminar experiment, A.E7 T cells were
anergized with platebound anti-CD3. Some cells were left unstimulated as a non-
anergized control (1). Following 5 days of rest, anergic cells were electroporated with
media alone (2) or 20 nanomoles of control siRNA (3) or Egr-2-specific siRNA (4).
Knockdown of Egr-2 protein was confirmed 2 days later (7 days of rest-data not shown)
and the cells were then submitted to antigen rechallenge (12 days ofrest). There was no
effect on the ability to proliferate in response to antigen rechallenge in anergic cells with
Egr-2 knockdown compared to those electroporated with control siRNA. In this
experiment there does appear to be a nonspecific effect of siRNA on anergic
unesponsiveness.
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Legend to Figure 21: Treatment with two independent Egr-2-specific siRNAs prior to
anergy induction results in effective knockdown of Egr-2 and rescues anergic cell
unresponsiveness to antigen rechallenge. A.E7 T cells were electroporated with the
following: media alone (2-none), control irrelevant siRNA (3-con), or one of two distinct
nonoverlapping siRNAs specific for Egr-2 (4-Egr2-7 or 5-Egr2-8). Electroporated cells
were rested for 4-6 hours before being anergized. A population of cells was
electroporated with media alone and left unstimulated (resting) as a responsive control (l-
none). (A) Cells were analyzed for Egr-2 gene silencing by flow cytometr 5 days after
removal from the anergizing stimulus. (B) Also at day 5 , protein was extracted from the
cells for analysis by western blot. The membrane was then stripped and reprobed with
antibody against B-actin to verify equal loading. (C) Proliferative responsiveness to
antigen rechallenge was assessed by eH)- thymidine incorporation into DNA and by (D)
CFSE cell division history with flow cytometr. Cells were labeled with CFSE and then
stimulated with syngeneic splenocytes plus or minus Pcc. The light histogram in each
graph represents CFSE fluorescence in cells not exposed to antigen (0 divisions) while
the heavy histogram represents fluorescence in cells stimulated with lOj.M PCc. CFSE
fluorescence decreases two- fold with each division. While 97% of resting cells have
proliferated at least once when rechallenged with antigen, only 52% and 49% have
proliferated in anergic cells with no siRNA or control siRNA, respectively. Cells treated
with Egr-2-specific RNA have 73% proliferating cells.
Egr-2 is required to establish the block in ERK
horylation
In collaboration with Ken Bishop, ERK phosphorylation was analyzed in A.E7 T
cells in response to platebound anti-CD3 mAb plus soluble anti-CD28 mAb. Ken
optimized the time required for stimulation of resting A.E7s to observe ERK
phosphorylation by western blot with an antibody against phospho-ERK and determined
that 45-90 miutes of stimulation resulted in peak phosphorylation of ERK- l and ERK-
while levels of total ERK- l and ERK-2 protein were unchanged.
We then used these conditions to analyze ERK phosphorylation in anergic cells
that had been treated with media alone, control siRA, or Egr-2-specific siRA. A
population of cells was electroporated with media alone and left unstimulated as a non-
anergic control. Cells were treated as indicated, rested for 4-6 hours, and anergized for 12
hours. The cells were then removed from the stimulus and after 5 days Egr-2 protein
levels were analyzed by flow cytometr and western blot. On rest day 6, the cells were
stimulated with platebound anti-CD3 mAb plus soluble anti-CD28 mAb for 60 minutes
removed from the stimulus and processed for protein isolation. Thi micrograms of
protein was run on an SDS protein gel, transferred to PVDF membrane , and probed with
anti-phospho-ERK antibody. The blot was then stripped and repro bed with anti-ERK
antibody (Figue 22). It is apparent that, while anergic cells are defective in their ability
to phosphorylate ERK- l and ERK-2 in response to stimulation compared to resting
control cells, Egr-2 gene silencing in anergic T cells restores this ability.
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Legend to Figure 22: siRNA-mediated gene silen.ing of Egr-2 in anergic cells results in
increased ERK phosphorylation in response to stimulation. A.E7 T cells were
electroporated with the following: media alone (2), control irrelevant siRNA (3), or one
of two distinct, nonoverlapping siRNAs specific for Egr-2 (4-Egr2-7 or 5-Egr2- 8).
Electroporated cells were rested for 4-6 hours before being anergized. A population of
cells was electroporated with media alone and left unstimulated as a responsive control
(1). Following 6 days of rest, cells were stimulated with immobilized anti-CD3 mAb and
soluble anti-CD28 for 60 minutes, removed from the stimulus, and protein was isolated
for western blotting with anti-phospho-ERK. The blot was then stripped and reprobed
with anti-ERK antibody to verify equal protein loading. Arowheads mark ERK- I (top)
and ERK-2 (bottom).
Discussion
It has been well documented that stimulation of T cells through the TCR in the
absence of costimulation can result in long-term hyporesponsiveness to rechallenge
termed anergy. Although the anergic phenotye has been well studied in vitro and in
vivo, the molecular events responsible for the induction and maintenance of anergy are
sti1largely a mystery. Anergic cells appear to have at least two defects when stimulated;
1) a block in T cell signaling, evidenced by ERK hypophosphorylation, Ras
hypo activation and Rapl hyperactivation and 2) repression of the IL-2 promoter and/or
activators ofIL-2 transcription. Some candidates have been published that may playa
peripheral role in the anergic phenotye, but none has been demonstrated to be required
for anergy. Anergy is most likely a complex process involving a number of genes that
serve to mediate the blocks to rechallenge mentioned above.
I have demonstrated that the A.E7 T cell line can be anergized in vitro by
stimulating the cells with platebound anti-CD3 monoclonal antibody (mAb) in the
absence of co stimulation, an observation that confirms the findings of other groups
(17;23;33-35;39). The induction of the anergic phenotye can be avoided by
co stimulating the cells with soluble anti-CD28 mAb which results in much greater IL-2
production, proliferation and, after a suffcient rest period, a greater responsiveness to
rechallenge with syngeneic APCs plus antigen. It is evident that the minium period of
rest required after an anergizing stimulus before rechallenge is 5 days. At a shorter rest
period, although the anergized cells are indeed unesponsive to rechallenge , the activated
control cells are equally unresponsive, an observation consistent with published reports
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that activated T cells must have a period of rest before regaing responsiveness to
stimulation. The activated control is importnt in the study of anergy because one must
be careful identifying T cell unesponsiveness as anergy, when in fact the observed
hyporesponsiveness could be simply a result of rechallenging the cells too soon after
even productive stimulation. Whether this early unesponsiveness to rechallenge in
productively stimulated cells is due to the same factors as long-term anergy has not been
resolved. It wil be interesting to answer this question when molecular mediators of the
anergic phenotype have been identified and tested for association with early post-
stimulation unresponsiveness. In the following discussion concerning expression levels of
potential anergy mediators at various time points following the initial anergizing
stimulus, it should be noted that until activated control cells are responsive to rechallenge
(identified in this study to be 5 days), hyporesponsive cells cannot be truly considered
anergic. When "anergic cell population" and "activated control population" are used
throughout this discussion, these descriptions wil refer to the phenotwe observed in the
populations after at least 5 days of rest, regardless of the time being examined.
In terms of the activated cell population, used as a control for anergy, it is
important to note that while these cells are responsive to antigen at high doses and appear
to respond to the same extent as mock-stimulated control cells , at low antigen doses they
appear to be anergic. Although these cells wil be referred to as "activated" and
responsive" controls throughout this discussion, we could more accurately call these
cells "parially anergic . This may be useful in the future when correlating molecular
events associated with anergy--ne would expect that the activated population may
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manifest an anergic phenotype at a low antigen dose while overcoming these limitations
at higher doses.
I chose the earliest timepoint of 12 hours to examine anergic expression profies
because it allowed time for the upregulation of genes that have a slow induction rate in
response to stimulation. However, this approach wil not identify genes that are
differentially expressed transiently, disappearg before l2 hours. Indeed, one such gene
named GRAL, has been published that the authors have suggested plays a role in anergy
induction, antagonizing IL-2 transcription in cells that do not receive costimulation (42).
The authors report that GRAL is upregulated transiently (durg the first few hours of
stimulation) only in cells stimulated through the TCR in the absence of co stimulation
and that overexpression of GRAIL leads to IL-2 suppression. However, it can be argued
that such a gene only plays a peripheral role in anergy induction-that it obligates a T
cell to receive co stimulation in order to prevent its upregulation and allow IL-
production; which, incidentally, results in anergy avo idance. Put another way, since
anergy can be induced even in fully stimulated cells (such as in the presence of
rapamycin), anergy can be induced in the absence of GRA. Genes like GRAL, which
wil not be identified in this screen, hold a limited interest since they are not present long-
term (beyond a few hours) and don t appear to have a diect effect on the upregulation of
anergy factors.
The hypothesis offered by Powell et al. (25), that anergy genes wil be expressed
early in both anergized and activated T cells and then downregulated in the proliferating
activated cells, is convincing but incomplete. Indeed, I wil refer to factors that follow
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this pattern as anergy induction genes, in contrast to anergy maintenance genes. I make
the distinction because early genes necessary for the anergic phenotype may serve simply
to induce other factors that actually mediate the molecular events responsible for anergy.
If this is tre, genes following the hypothesized pattern are importnt in that if they are
prevented from being expressed long-term, anergy wil not follow. However, they may
play little or no role in diectly mediating the hyporesponsiveness of a T cell to
rechallenge. If an identified anergy induction gene were eliminated after it has
upregulated an effector or maintenance gere, there would be no effect on the
rechallenged phenotype. However, if the gene were prevented from being upregulated (as
is thought to be the case with CSA treatment of anergized cells), it would have a
profound effect on the rechallenged phenotye, resulting in a cell that is responsive to
antigen rechallenge. If this assumption concerning both induction and maintenance genes
is correct, then one might expect to see maintenance genes not being expressed until later
times, after the induction genes have initiated their transcription. These maintenance
genes would be differentially expressed from the star. Such genes need not follow the
pattern in order to be essential for anergy maintenance, because if the induction gene is
not activated, then the maintenance genes would not be upregulated and anergy would
not follow. Again, these genes I would call maintenance genes and would expect these
proteins to have direct effector fuctions at key points in signaling and transcription in
stimulated anergic cells. Of course, it is possible that a single gene could have both
induction and maintenance effects, and this scenario wil be considered in the discussion
of the candidates themselves.
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The analysis of Affymetrx GeneChip data from anergic and control cells at three
times following the primar stimulus was revealing about the events occurrg in anergy
induction when compared to full activation. If the model of anergic factor upregulation
described by Powell et al. (25) is accurate, it would follow that the earliest timepoint
analyzed in this study, after l2hr of stimulation, would demonstrate no difference in
expression of "anergy factors" between the anergized population and the activated
control. In fact, that appears to be the case-although many genes are differentially
expressed in anergic cells compared to mock-stimulated control cells at this early time, I
identified only two that are significantly differentially expressed between anergic and
activated control cells in all three replicate experiments. The first is IL-2 , which is
slightly upregulated in anergic cells over mock-stimulated controls (more than 1.7 fold)
but is expressed to a much greater extent in the activated control. This was an expected
result as anergized T cells fail to produce IL-2 at the same level as productively
stimulated cells (l7) but stil produce some IL-2 in response to stimulation. It is precisely
this difference that appears to mediate the induction of anergy in partially stimulated
cells. Therefore, IL-2 served as an excellent internal control to determine the success of
the microarray hybridization and analysis. The slight upregulation of IL-2 in anergized T
cells at this time point does not appear to be suffcient to induce proliferation and
ultimately, anergy avoidance.
The second gene identified at this time was Grane B , a secreted perfori
tyically produced by cytotoxic T cells and natual killer cells; it has the ability to induce
apoptosis in the target cell (61 ;62). Implications of anergic cells making cytotoxic
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substances include a role in T cell suppression-it is possible that an anergic cell could
use cytotoxic substances to kill an APC presenting antigen to it, resulting in a decrease in
antigen presentation to other potentially reactive T cells. Anergic cells have been reported
to suppress T cell activation (57) and others have reported the ability of anergic T cells to
kill antigen presenting cells (63), but the A.E7 cell line does not suppress activation in
vitro (R. Schwartz , personal communication). The differential expression of Granyme B
narrowly fulfills the requirements set forth for anergy candidates, that the gene be up- or
downregulated at least 1.7 fold in anergic cells as compared to both mock-stimulated and
activated controls. The question remains whether this is a tre anergic factor
differentially expressed prior to proliferation in the activated control (negatively
regulated by CD28 stimulation) or if it is simply an arifact narrowly passing the criteria
out of over 36 000 expressed sequences. The paucity of differentially expressed factors at
this early time prior to proliferation supports the model offered by Powell et al. (25).
Notable genes differentially expressed in anergic cells at day 5 of rest include
Bace- , Osteopontin, Neuritin, Pac- , Egr- , and two ESTs-AKOll 178 and AI152781.
Beta-APP cleaving enzyme-2 (Bace-2) is a transmembrane protein located in the cell
membrane, golgi apparatus, and endosomes (64). Bace-2 message is expressed in a large
number of tissues including brain, hear and pancreas. There is moderate expression of
Bace-2 in lymph nodes , low expression in spleen, and no detectable expression in thymus
or blood leukocytes (65). Bace-2 is homologous to another protein, Bace- , and both
enzymes possess secretase activity, meaning that they can cleave other membrane-bound
proteins , releasing them (secreted) from the cell. The most studied target of the Bace
I$!
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enzes is p-APP, a protein that, when cleaved, accumulates in senile plaques in
Alzheimer s disease (66). While Bace- l has signficant p -secretase activity of p - APP
Bace-2 has much less. Bace-2 also acts as an a-secretase (64) and it is currently unclear
what physiological role Bace-2 has in the brain. Bace-2 expression has not yet been
reported in T cells. A recent report has shown that, in cultued cells, its homolog, Bace-
localizes to the lipid raft (67), a very important strctue for T cell activation. I have had
two different antibodies made to this protein, targeting the extracellular domain. Ken
Bishop has made a Bace-2 expression vector and shown that both antibodies recognize
protein from Cos cells transfected with this vector. It wil be interesting to see if the
antibodies confirm differential protein expression of Bace-2 in anergic cells and whether
the antibodies wil be useful for flow cytometr. Because Bace-2 is a cell surface protein
flow cytometr and cell sorting could be performed to isolate live, Bace-2-expressing
cells. In addition, experiments could be performed using these antibodies as blocking
agents to assess the role of extracellular Bace- enze activity in T cell anergy.
Osteopontin is a secreted cytokine well- studied in bone dynamics as well as the
imune system. It has been reported to have alternate splice forms and multiple post-
translational modifications, resulting in numerous different proteins, each with unique
activities. Osteopontin is essential in the pathogenesis of experiental autoimune
encephalomyelitis (EAE), as the osteopontin knockout mouse is more resistant to
induction ofEAE as well as its progression (68). One of the primary functions of
osteopontin is as a chemoattactant for T cells and macrophages; the knockout mo use has
limited macrophage accumulation in damaged tissues (69). Other groups have identified a
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role for osteopontin in rheumatoid arhrtis (70). While all of these reports suggest a
proinflammatory role for osteopontin rather than one consistent with decreased T cell
responsiveness , there are other possibilities. First, the many different isoforms and
modifications of osteopontin could result in one that has a blockig effect, preventing
macrophage accumulation. Another possibility is that osteopontin has an as yet
unidentified, direct role in preventing T cell activation. Third, and possibly most
interesting, stems from the discovery that two independent companies have observed
upregulation of osteopontin in CD25+ suppressor cells following activation
(conversations with representatives at Keystone conference). It is possible that
osteopontin has direct suppressive effects on T cells or macrophages, or that its role is to
cause migration of macrophages to areas of tolerance induction. One of the companies
that identified osteopontin secretion in CD25+ suppressor T cells displayed data using an
ELISA kit. I have obtained this kit and we are prepared to test anergic cells for the
secretion of this protein.
Neuritin has recently been discovered, and is upregulated in neurons that were
stimulated to promote neurte outgrowth. It is a GPI-anchored protein that localizes to the
cell surface. Addition of soluble recombinant neurtin to cultued neurons miicks
stimulation, suggesting that neuritin binds a receptor on the cell surface to induce an
activation signal (71). Neuritin s GeneChip expression pattern is strkingly similar to that
of Bace- , and could be examined as a potential target of Bace-2 secretase activity,
resulting in a secreted product-possibly with immune-modulating activity.
106
Phosphatase of Activated Cells- l (Pac- I) is a well-studied protein that is quickly
upregulated in stimulated T cells, migrates to the nucleus , and has MA kinase
phosphatase activity (72). Constitutive expression of Pac- l inhibits MA kiase activity
normally induced in response to T cell receptor crosslinkng, resulting in decreased
activation of ERK - 1 and ERK - 2 and decreased transcriptional activity of c- fos (73). The
potential significance of this protein to anergy maintenance is paricularly evident given
the fact that there has been a well-demonstrated defect in ERK phosphorylation in
stimulated anergic cells (25;35). In fact, Li et al. even suggested that this defect may be
due to eitrer Pac- lor another protein phosphatase induced in anergic cells (34). At the
same time, another group reported that Ras is defective in stimulated anergic cells
suggesting that this explained the defect in ERK activity (35). However, it is possible that
anergic cells utilize two approaches to limit signaling through the MAP kinase cascade.
It is worth noting that upon close examination by Ken Bishop, one of the ESTs
differentially expressed in anergic cells, AK011178 , shares some identity with
RhoGAP8 , a GTPase that inactivates Rho by cleaving GTP within the active fOrm. This
method of inactivation is also one way Ras is inactivated, so AKO 11178 could be pursued
as a potential RasGAP. Even if this EST does not have RasGAP activity, inhbition 
Rho can have major consequences on changes in the cytoskeleton and therefOre also on
imune synapse formation and T cell activation. This EST is being investigated fuher
to elucidate its potential role in anergic T cells.
Early Growth Response-2 (Egr-2), fIrst identified in a fibroblast cell line to be
induced within minutes after serum stimulation (74), is a member of the famly of early
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growth response zinc- fmger transcription factors. This family is a particularly well-
studied group, and consensus binding sites (75-79) and target genes (Table 1) (74;75;80-
95) have been reported. All four members of the Egr family are expressed in T cells in
response to mitogenic stimulation (79;96- 102). Transcription of Egr-2 and 3 is blocked
when T cells are pretreated with cyclosporine A (CSA) while Egr- I transcription is
reported to be superinduced at the mRA level (96;103). This suggests that: l) Egr2 and
3 transcription is NFAT-dependent, 2) Egr- l transcription is independent ofNFAT and 3)
possibly Egr- l is negatively regulated by a CSA-sensitive protein. These are important
observations, since CSA has been reported to block the induction of anergy as well (17).
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Legend to Table 1: Genes reported to be targets ofEgr transcription factors.
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The fuctional regions of Egr-2 DNA-binding and transcriptional activities have
been mapped. It appears that only the zinc fmgers (C-termal) are required for DNA
binding while two domains located N-termal to the zinc fmgers are responsible for
transactivation. Deletion of these regio ns completely abolished the activating ability of
Egr-2 without affecting DNA binding or nuclear localization (104).
Egr-2 and Egr-3 have so far been implicated only in activating transcription at the
Fas ligand promoter. In fact, either factor alone is able to induce transcription ofFas
ligand (80;101). This was an obvious first choice to pursue for the fuction of Egr-2 in
anergy, however I found no increase in Fas ligand transcript in anergic cells on the
GeneChip or protein expression on anergic cells using flow cytometry (data not shown).
The lpr mouse is a natual Fas ligand knockout that has a severe systemic lupus
erythematosus (SLE)-like syndrome (105). Since Egr-2 and 3 activate transcription of
FasL, peripheral T cells from the lpr mouse were examed for Egr-2 and Egr-
expression and it was discovered that they constitutively express Egr-2 protein at a very
high level; comparable in fact, to wild-type T cells stimulated with PMA and Ionomycin.
Egr- 3 was not constitutively expressed (101). As a natual mouse model overexpressing
Egr- , it is interesting to note that Zpr T cells are hyporesponsive to in vitro stimulation
with concanavalin A (Con A), failing to make IL-2 or proliferate; they also appear to
have a decreased responsiveness to ConA stimulation plus exogenous IL-2 (106;l07).
These cells make normal amounts ofIL-2 when PMA is added to the stimulation (108).
Despite the defect in IL-2 production lpr T cells produce normal amounts of IFN-
(109). Zpr T cells also have elevated Fyn kinase activity due to increased levels ofFyn
if.
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protein (1l0). Apart from the decreased responsiveness to IL-2 , this description of Zpr 
cells correlates perfectly with T cell clonal anergy (32; 111; 112). While I cannot rule out
the effects of a disrupted FasL pathway in these cells, it is possible that Egr-2 induces the
hyporesponsive phenotye and increased Fyn levels in Zpr mice. One unesolved issue is
that if these cells are hyporesponsive in vivo as well, why do they exhibit severe
autoimune disease? It is possible that a small responsive subpopulation of T cells
escapes programmed cell death in vivo, homes to the proper site of autoantigen, and
proliferates, causing destruction of tissue. However, this population may not be large
enough to proliferate to a large extent in vitro.
Another observation is that Egr-2 is induced in fibroblasts when they are treated
with TGF- (113). Since treatment with TGF- has been demonstrated to induce anergy
in stimulated T cells (1l4;ll5), it would be interesting to exame ifTGF- also induces
Egr-2in T cells.
GeneChip analysis revealed that Egr-2 expression followed the pattern of an
anergy factor" according to the model hypothesized by Powell et al. (25). This was
confIrmed by RT-PCR. Whle Egr-2 protein was equally upregulated in anergic and
activated cells prior to proliferation, it was downegulated in activated controls at
approximately rest day 3- , which coincides with the time of greatest proliferation in this
population. This suggests that, indeed, proliferation may be responsible for the
downregulation of Egr-2. Protein levels remained detectable in anergic cells by western
blot through rest day 9 in this experient, demonstrating that the factor is present durng
rechallenge and the observed hyporesponsive phenotype. When cells were anergized and
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then rested with or without exogenous IL-2 to break anergy, Egr-2 protein levels dropped
quickly in the anergic cells exposed to IL- , again coinciding with proliferation. This
shows excellent correlation of Egr-2 expression with the anergic phenotype , since
stimulation of anergic cells exposed to IL-2 for 10 days demonstrated dramatically
increased responsiveness of these cells.
Interestingly, Egr- l is an activator of IL-2 transcription, binding to specific Egr
consensus sites in the IL-2 promoter (91;116;117). However, in one study, Egr- , 3 and 4
did not bind the promoter as assessed by EMSA in Jurkat T cells (91), suggesting that
Egr-2 does not directly affect IL-2 transcription. Others reported that Egr- l acted on its
own promoter to repress transcription, in a negative feedback loop (75). This opened the
possibility that Egr-2 may repress IL-2 transcription indirectly by repressing Egr- l. For
this reason, I decided to study the kietics ofEgr- l and Egr-2 protein expression in
previously mock-stimulated, anergized and activated cells to determine if Egr- l is indeed
repressed in anergic cells durng rechallenge. After a suffcient rest period following
mock-stimulation, anergy induction or activation, cells were stimulated with platebound
anti-CD3 mAb plus soluble anti-CD28 for varous times and protein expression was
analyzed by western blot. As expected, Egr-2 protein level was high in anergic cells prior
to stimulation and increased in all populations shortly after. Egr- l was not expressed by
any of the three populations prior to stimulation and was quickly upregulated in
previously mock-stimulated cells. Interestingly, Egr- l expression was very weak
following stimulation in anergic cells.
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This pattern was also observed when the same populations were rechallenged
with APC' s plus antigen (at a high or low dose) and protein evels of both Egr- l and Egr-
2 were analyzed by flow cytometr. Again, Egr-2 protein level was selectively higher in
anergic cells prior to stimulation and quickly upregulated in all populations at both
antigen doses. The fact that anergic cells are able to increase Egr-2 protein levels is
interesting, considerig the defect in signaling as well as the lack of AP- l-mediated
transcription in these cells. Either the signaling block is incomplete, allowing only factors
requiring a low threshold of stimulation to be upregulated, or the block is selective and
pathways upstream of Egr-2 are unaffected--ither is possible. First, Crespi and
colleagues reported that bypass of the MAP kiase block with a transfected Ras mutant
that is constitutively active cannot abrog;te anergy induction (38), challenging the theory
that the MAPK signaling block is necessary for anergy maintenance. Second, Egr-2 is
NFAT-dependent (CSA blocks its expression) and anergic T cell clones do not have a
calcium mobilization or NF A T transcription defect (31). It is possible that Egr-2 is not
dependent on an intact MAK cascade for upregulation in T cells. Supporting this latter
hypothesis is the observation in B cells that a chemical inbitor of the ERK branch does
not affect Egr-2 induction (1l8).
In contrast to the responsiveness of anergic cells demonstrated by Egr-
upregulation, anergic cells are severely defective in the ability to express Egr- l following
stimulation. This is evident in both the western blotting and flow cytometr. At both high
and low antigen concentrations, Egr- l expression is blunted in anergic cells at the peak
time of expression and rapidly retus to pre stimulation levels. This is also the case to a
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milder extent in previously stimulated control cells. This observation has not been
previously reported, and is a similar result to what has been obsened with fos and jun
proteins in stimulated anergic cells (31), also activators ofIL-
Since Egr- l expression was indeed inbited in anergic cells, I chose to develop a
transient transfection assay to assess if Egr-2 could repress Egr- l promoter activity. I
obtained a CMV-Egr2 expression plasmid (P. Mittelstadt, NIH, Bethesda, MD) and a
chloramphenicol acetyltransferase (CAT) reporter vector drven by the Egr- l promoter
(X. Cao, National University of Singapore , Singapore). Jurkat T cells were transfected
with both plasmids , stimulated with platebound anti-CD3 mAb, and processed for CAT
activity. Although no strong inhbition of the Egr- l promoter by Egr-2 was evident, the
lack of a transfection control plasmid made it diffcult to draw conclusions from the data
(data not shown). Additionally, it has since come to my attention that the CMV promoter
is not a paricularly effective promoter in T cells (L. Berg, UMASS , Worcester, MA), and
therefore it is possible that significant expression of Egr-2 was not obtained in these cells.
Became the IL-2 promoter contains putative Egr-2 binding sites, I utilized an IL-
expression assay to assess if Egr-2 has an ability to repress the IL-2 promoter. Oddly,
although EL-4 T cells make large amounts of IL-2 with anti-CD3 and anti-CD28 mAb
stimulation, no IL-2 promoter-driven luciferase is detectable in these cells when
stimulated under the same conditions. Others have also made this observation in other T
cell lines (discussions at meetings). Because of this phenomenon, EL-4 cells transiently
tranfected with an IL-2 promoter-drven luciferase plasmid were stimulated with PMA
and Ionomycin, which resulted in large amounts of luciferase being produced. Under
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these conditions, CMV promoter-drven Egr-2 had no effect on IL-2 promoter activity.
This result could be explained by the fact that, while Egr- l binds and activates the human
IL-2 promoter, Egr-2 does not bind (9l). I felt that, despite this report, it was important to
test Egr-2 action on IL-2 transcription because it was possible that Egr-2 acted differently
in mouse T cells or that it repressed IL-2 transcription indirectly by either 1) repressing
an activator of IL-2 or 2) activating a repressor of IL-2. I was unsure if such an indirect
action would be detectable using a transient transfection assay, given that the IL-2-
luciferase reporter plasmid is present in many copies in transfected cells and might prove
overwhelming to endogenous transcription mechanisms. Another diffculty with this
approach is that, in order to elicit IL-2 promoter activity, it required stimulation of
transfected cells with PMA and Ionomycin-mitogens that result in maximal T cell
stimulation and bypass upstream signaling pathways. If Egr-2 upregulated a factor that
blocked signaling, PMA and Ionomycin stimulation would bypass the block in this assay.
It is also possible that PMA and Ionomycin stimulation is so powerful that it can
overcome a transcriptional block. In fact, PMAIonomycin stimulation abrogates the
anergic phenotye, resulting in IL-2 secretion and proliferation of anergized T cells
(34;35;112) (and unpublished results). In addition to the IL-2 promoter, I also tested the
fosB and jun promoters, which contain Egr-2 binding sites and were reported to be
altered in anergic cells (3l). Again, using the same Egr-2 expression plasmid, I found no
effect of Egr-2 on the activity of either promoter in response to PMA and Ionomycin
stimulation.
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Because of the limitations of the transient overexpression assays mentioned
above, I chose to create stable EL-4 clones expressing Egr-2 and then analyze them for
growth impairments and endogenous IL-2 production defects. The stable transfection
resulted in two clones that made protein detectable by western blot. One clone, 5D3
expressed protein that was larger than the expected size and one, 5Cl , expressed Egr-2 of
the appropriate size. Interestingly, clone 5Cl grew much slower than the others. When
5C 1 cells were stained with PI and analyzed by flow cytometry, a large percentage
(11.5%) fell within the dead gate, while controls had only 2- 5% fall withi this gate.
The 5C 1 and control clones were subcloned by limiting dilution to obtain cell lines from
single cells. These subclones were also analyzed by PI staing and four subclones from
the 5Cl stable cell line all grew very slowly and 22-45% of the cells fell in the dead gate
while controls had only 2-5% dead cells (data not shown). The observation that Egr-
overexpression ImY induce cell death is consistent with the fact that anergic cells
undergo a wave of cell death after rest day 5 (17). Also consistent with these
observations, Unoki and colleagues reported that Egr-2 expression is induced after
overexpression of PTEN and that expression was decreased in a large number of ovaran
tuors compared with corresponding normal tissues. When Egr-2 was overexpressed in
tuor cells lines, it suppressed the growth of these cells significantly. Antisense
oligonucleotides for Egr-2 effectively inhbited its expression and accelerated cell growth
(119).
The stable clones were subjected to antibody stimulation and analyzed for IL-2
production by ELISA. There was varability among the clones in IL-2 production, even
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between the two controls tested. The stable clone producing Egr-2 at the correct size
5C 1 , produced normal amounts of IL- 2 in response to stimulation in three separate
experiments. Interestingly, clone 5D3 , which produced a slightly larger Egr-2 protein
product than expected, produced extremely low amounts of IL-2 in response to
stimulation in all three experiments. This clone did, however, produce large amounts of
IL-2 in response to PMA and Ionomycin stimulation. Since I have not pursued this effect
further, I am unable to make any conclusions about the state ofIL-2 transcription in trese
cells compared to control clones. Because only two stable clones tested positive for Egr-
by western blot (one at the expected size, one larger than expected), it is difficult to base
any meanngful conclusions on data generated from the clones. Altho ugh one clone had a
severe growth defect with increased cell death and one had a defect in IL- 2 production
neither clone manifested both defects. The observed phenotyes of these clones could
simply result from differences in the original cell that established the clone, since
varability is expected within a transformed cell line cared in vitro.
I next chose to examne our in vivo model of tolerance induction, the mouse
tolerized to a ski allograft after treatment with DST and anti-CD40L. Because of the
association of suppressor T cells with tolerance induced by this method (120) as well as
the association of anergy with cells that are suppressed (56), I chose to examine the
lymph nodes draining the graft of long- term allotolerant mice for expression of Egr-2 by
flow cytometr, hypothesizing that suppression would occur in the lymph nodes and
would -be present long- term. In a preliminary experient, 2 of 3 tolerant mice had an
increased percentage ofCD4+ cells from the drainig nodes that fell within the Egr-
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high gate compared to control mice and compared to tolerant mice in non-drainig nodes.
Analyzing mice with long-term grafts is diffcult because, since "tolerant" mice
eventually do reject their grafts, I can t know whether or not a long-term recipient is in
the process of losing tolerance and in the early stages of rejecting the graft. In addition
although it is likely that T cell suppression occurs in the lymph nodes draining the graft
it is possible that suppression occurs in the graft itself, a location diffcult to inspect for
Egr-2-expressing cells. Further, tolerized cells may not remain in the draining lymph
nodes but may leave them to circulate in the blood stream or migrate to extranodal sites
an observation made in the Jenks soluble antigen model of tolerance (49). Others in the
lab have explored the effect of depleting CD25+ cells in grafted mice on tolerance
induction. If CD25+ cells are depleted immediately prior to and/or during tolerance
induction with DST and anti-CD40L, grafts are rejected more rapidly, implicating T cell
suppression in the induction phase of tolerance (S. Banuelos , unpublished results). These
observations are important because it is possible that suppressed anergic cells would best
be identified early in tolerance induction and may be best observed in the blood of these
animals. I have not explored in vivo Egr-2 expression fuher, but this is an interesting
venue to pursue.
With the demonstration of a correlation between Egr-2 protein expression and the
anergic phenotye in vitro, I wanted to explore whether Egr-2 had a causative role in
anergy. I crose siRNA-mediated gene silencing as the method to test this theory. As
described above, if anergic factors that playa role in the maintenance of anergy are
knocked down in anergic cells late in the process but before antigen rechallenge, I would
119
expect to observe increased responsiveness to rechallenge. Conversely, if the factor were
only an induction factor, knockdown at some time after it has induced other effector
molecules would have no effect on responsiveness to rechallenge. For this reason, two
approaches were designed to assess the effect of siRNA-mediated Egr-2 knockdown.
First in a prelimiar experiment, A.E7 T cells were anergized, rested for 5 days , and
then electroporated with Egr-2 siRNA or control siRNA. Cells were assessed two days
later (rest day 7) for the effectiveness of knockdown by flow cytometr. After observing
significant knockdown of Egr-2 levels in these anergic cells, I then proceeded to submit
the cells to antigen rechallenge (rest day l2). The cells with greatly reduced levels ofEgr-
2 demonstrated no increased responsiveness to stimulation over controls. This suggested
that either Egr-2 was not necessar for direct effector fuctions in anergic T cells , or that
Egr-2 protein was not reduced suffciently on rest day 12 to observe these effects.
Next, resting A.E7 T cells were electroporated with Egr-2 siRNA, allowed to
recover for a few hours, ficolled to remove dead cells , and anergized. These cells were
assessed two days after removal from the stimulus (rest day 2) for Egr-2 knockdown by
flow cytometry. Analysis demonstrated that Egr-2levels were marginally affected by
siRNA treatment at this time. This was not surrising, considering the massive amounts
of Egr-2 produced upon stimulation, as evidenced by mRA levels on the GeneChip and
by RT-PCR and protein levels by western blot and flow cytometry. When cells were
analyzed three days later (rest day 5), an increased proportion of cells (76% vs. 55%)
treated with Egr-2 siRNA expressed very low levels of Egr-2 compared to controls as
assessed by flow cytometr. Knockdown was confirmed by western blot. Evidently Egr-
l20
siRNA needs time to "catch up" after the intial bolus of Egr-2 production following
stimulation.
The mild effect of Egr-2 knockdown as assessed by flow cytometry is contrasted
by a much larger apparent effect when analyzed by western blot. This discrepancy may
be explained by the very different approach each method takes to quantify protein levels.
Flow cytometr was initially my method of choice, because it provides information on
protein level in each cell. Western blotting only indicates the total amount of protein
expressed in an entire population of cells. For example , if 50% of a population of cells
has 100% knockdown of Egr-2 protein, then flow cytometr wil show two peaks, each
with 50% of the cells in it. One wil represent a low-staining population with no Egr-
and the other a higher staing peak with normal levels of Egr-2. If 100% of the cells only
reduce their protein levels 50%, then flow cytometry wil show one peak that contains
100% of the cells that stain at 50% of the control anergic population. In both scenaros
analysis by western blot wil report the same result -a 50% reduction in protein.
Because of this phenomenon, it appears that flow cytometr provides more
information about the entire population of interest. However, it is likely that flow
cytometr is limited by a threshold of detection-a lower limt of protein that must be
present in a cell in order for staining to be bright enough to exceed background. In this
case, cells that contain Egr-2 protein at levels just below this threshold (whatever it may
be), wil be in a low-staining peak at background level, representing an Egr-2-negative
population. These "below threshold" cells wil have the same fluorescence as cells that
have 100% reduced Egr-2 levels. As observed in the experiments when cells are treated
l2l
with siRNA prior to anergy induction, even control anergic cells have a high and low
stainng peak. The low peak in these cells rmy represent cells makg Egr-2 below
threshold (which may be a high level) while this same peak in cells with Egr-
knockdown may have no Egr-2. So, when cells with Egr-2 knockdown are analyzed by
flow cytometr and the result is an increase in the low-staining peak compared to control
anergic cells, there may actually be signficantly less Egr-2 in the low stainng peak of the
cells with knockdown compared to the same peak in controls. Because protein analysis
by western blot is additive over the entire population and therefore has no lower threshold
of detection on a per-cell basis , the same two populations compared with this method
may show a much more impressive difference in protein level. Adding another level of
complexity, western blotting is dependent on chemilumnescence for detection and
exposure to film. This can result in a narrow linear range that may limit quantification by
this method. In sumar, while flow cytometr provides more qualitative information
about the population, it may lose quaritative ability if there is a moderately high
threshold of protein detection per cell. While western blotting provides more quantitative
information about the total population, it fails to give the qualitative information about
expression in the cells of that population.
Anergic cells pretreated with siRNA as indicated were stimulated on rest day 7
and pulsed with trtiated thymidine after 48 hours to assess their responsiveness to
antigen rechallenge. Cells that had been treated with Egr-2 siRA showed increased
responsiveness to rechallenge compared to untransfected and control siRNA-transfected
cells. In another experient, these cells were first labeled with CFSE , mixed with
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stimulator APC' s plus PCC antigen, and assessed for proliferation by flow cytOIretry 4
days later. As observed with tritiated thymidine incorporation, cells with reduced levels
of Egr-2 were more responsive than either untransfected or contol-transfected cells to
antigen rechallenge , resulting in increased proliferation assessed by CFSE dilution. This
result implicates Egr-2 as an anergy induction gene, since in a preliminary experiment
protein knockdown at day 5 with antigen rechallenge at day 12 appears to have no effect
whereas early knockdown by transfecting siRNA prior to anergy induction results in
rescue of antigen responsiveness in anergic cells. Because Egr-2 is a transcription factor
I am currently looking at the expression of late anergy candidates in siRNA- treated cells
(potential maintenance effector genes) to assess ifkrckig down Egr-2 prior to anergy
induction affects their expression.
Because Egr-2 knockdown allowed anergic cells to recover the ability to
proliferate when rechallenged, I considered whether other aspects of the anergic
phenotype were also restored by Egr- 2 knockdown. One of the hallmarks of anergic cells
a defect in ERK- l and ERK-2 activity in response to stimulation, has been documented
(33;34). Defective phophorylation ofERK- l and ERK-2 has also been reported in
anergic cells, correlating with the loss of enze activity (25;35). In collaboration with
Ken Bishop, I observed that the defect in ERK phosphorylation in stimulated anergic
cells was corrected by Egr-2 knockdown.
Crespi et al. recently reported that constitutive Ras activation in primary T cells
was insuffcient to confer resistance to anergy induction via chronic TCR engagement
(38). This data suggests that while the block in the ERK arm of the MAP kinase cascade
, '-
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is a characteristic of anergy, it is not necessar for anergy maintenance; the
hyporesponsiveness of anergic cells may be maintained by redundant mechanisms. Other
groups have reported that active repression of the IL-2 promoter contributes to the
inability of anergic cells to transcribe IL-2 in response to stimulation (37; 121). If, in fact
there are multiple blocks utilized in anergic cells, it appears that Egr-2 is required for
inducing all of them, since its removal alone relieves anergic hyporesponsiveness. Whle
I have observed the rescue ofERK hypophosphorylation when Egr-2 is knocked down, it
is difficult to draw conclusions about direct Egr-2 involvement in other possible
pathways, since decreased ERK activity can contrbute to downstream defective AP-
activation and IL-2 production.
Interestingly, high expression of Egr-2 was found in other studies to be associated
with anergy, but the initial findings were not extended. Lechner et al. (60) screened for
genes expressed in priar T cells anergized in vivo, and reported the induction of Egr-
expression in the anergized T cell population. However, in these studies comparson was
made with purfied priary T cells stimulated with a mitogenic dose of anti-CD3 for l6
hours , a time point prior to the downegulation of Egr-2 and other putative anergy-
specific factors. Indeed these stimulated control cells also showed high Egr-2 expression
(60). In a second study of gene expression profies , Macian et al. (15) also observed
upregulation of Egr-2 following an anergizing stimulus but evaluated only early times
after T cell anergy induction, prior to proliferation in the activated control population.
Another study using microarays directed to tolerized B lymphocytes found high Egr-
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expression compared to unstimulated control cells (118), suggesting that Egr-2 may be
important in B cell tolerance as well.
Because Egr-2 knockdown after anergy had been induced may have little or no
effect on the responsiveness of anergic cells, and since Egr-2 is unikely to directly
inbit signaling components , I believe that the role of Egr-2 in anergy is primarly to
induce effector molecules that mediate the hyporesponsive phenotye. In collaboration
with Ken, I am searchig for Egr-2 targets of transcription that can regulate activation of
the upstream components of the MAP kinase cascade. In fact, one of the anergy
candidates upregulated in anergic cells at later timepoints is P AC- l-a protein with
demonstrated MAP kinase phosphatase activity. Another, AKO ll178 , is an EST that
appears to have homology to RhoGAP8 , a protein that inactivates Rho by converting its
GTP to GDP. This is signficant because Ras, the upstream activator ofthe MAP kinase
cascade, is inactivated in a similar way, leaving the possibility that AKOll178 could have
Ras-GAP activity. As mentioned in the introduction, many believe that anergic cells
upregulate a RasGAP, however, none has yet been identified. In addition to these two
candidates, there are a number of others that have yet to be characteried for their
fuction in anergy, including Bace- , neurtin, osteopontin, and other EST's.
The future for the project described in this thesis is very exciting, as the data
generated from the GeneChip screen has just begu to be tapped with the characterization
of the role for Egr-2 in anergy. It is possible that any of the other genes identified in the
screen could also playa significant part in the anergic phenotype. Approaches to fuher
characterizing other anergy candidates may take many different forms. One is to identify
those with the greatest differential expression to pursue first or those with characteristics
that make the most sense to anergy. I have begu this way, flagging the AKOl1178 EST
because of its impressive differential expression, Bace-2 because of its expression and
cell membrane localization, and Pac- l because of its MA kinase phosphatase activity.
A second approach would be to utilize other published microarray studies of
anergy, including those by Ali et al. , Lechner et al. , and Macian et al. (15;60; l22) to
cross-reference the genes induced in this system, including the many genes at rest day 2
with the large number of genes reported in the other systems to identify those worth
pursumg.
A thd approach may be to induce anergy in other ways or in other cells, in vitro
and in vivo, isolate RNA and perform qRT-PCR to analyze the expression of the
candidates and discover which are universally associated with anergy. This "subscreen
would be limited to a small number of caridates (i.e. the day 5 candidates described
above for which priers and conditions are already optimized) because qRT-PCR is not a
high-throughput method of analysis. A four, higher throughput approach would be to
design custom cDNA micro arrays to screen all of the candidates identified from all of the
timepoints (including the many on rest day 2).
Fifth, a fuctional approach to screening anergy candidates is to create expression
vectors for a number of them, transfect them into A.E7s (diffcult) or a transformed T cell
line like the EL-4 or Jurkat (easier), and screen the cells for disrupted IL-2 production.
Cells could be transfected with the candidate tagged with GFP, stimulated to produce IL-
, and analyzed by two-color flow cytometry with intracellular staining for IL-2.
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Sixth, an interesting approach that I have instituted, is to take advantage of the
fact that Egr-2 is necessar for anergy induction and that it could be the sole factor to
fulfill the pattern described by Powell and colleagues (25). This implicates Egr-2 as a
possible "master switch" that sets in motion the induction of the anergy effector
molecules , which have yet to be identified. From this hypothesis, one could search for
candidates that are induced by Egr- , involving the identification of candidates that are
not induced immediately with stimulation (not upregulated at the 12 hr timpoint) but are
induced and differentially expressed on day 2 or day 5. Genes following this pattern
include Bace- , AKOl1178 , andPac- l. Then, one can utilize genome databases to pull
out -2kb upstream of the transcription start site of these genes and scan them with a web-
based transcription factor binding site seach tool (such as TESS). Because Egr-2 binding
sequences have been well studied, it is relatively easy to determine if binding sites exist
in the promoter of a gene, the orientation in which it would bind, and how many sites
exist. After performng this search for Neurtin, Pac- , and Bace- , I have discovered an
Egr-2 binding site in each of the promoters, and two of the promoters have a single site
located on the negative strand and beging between 36 and 47 base pairs upstream of
the transcription star site. In contrast, irrelevant promoters (2 separate 2kb promoters of
housekeeping genes) or random DNA sequence (up to 10kb) did not contain a single site.
This is exciting-not only does it lend additional credibility to these factors in anergy,
but they may be the important effectors directly downstream of Egr-2. In addition, if this
small sequence at this location in a promoter responds to anergy induction (even if Egr-
alone doesn t induce it), then it could be lined to a reporter gene (GFP) and a transgenic
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mouse generated that would, in theory, produce green T cells when anergic. This would
allow visualization of the role of anergy in tolerance directly in vivo.
While there is much to be done concerning the other anergy candidates, exciting
opportties also exist for fuher study of Egr-2. First, because Egr-2 can be detected
using flow cytometr, more inspection of cells for Egr-2 expression could be performed
in mice tolerized to skin allografts using DST and anti-CD40L, the system instituted in
our lab. I have already shown some data on Egr-2 expression in T cells from these mice
but have only looked in mice with long- term grafts.
Second, one of the observations described above is that Egr-2 upregulation occurs
in stimulated anergic cells despite the block in the MAP kiase cascade and despite the
fact that jun (31) and Egr- l are not induced. This suggests that Egr-2 upregulation in T
cells in response to stimulation is independent of signaling through the MAP kinase
cascade, since each branch of the cascade (ERK, JNK, p38) as well as Ras activity is
defective in anergic cells (33-35). Interestingly, Schwarz reported that blockade of each
branch of the MAP kiase cascade through inhbitors (ERK and p38) or knockout mice
(JNK) does not inibit anergy induction (L. Luu, 1. Powell & R.H. Schwartz, unpublished
data, described in (30)). This lends additional support for the importce of Egr-2 in
anergy induction. It also may explain why anergic cells require exposure to their antigen
in order to remain anergic. Tanchot and colleagues describe a system of anergy induction
to peptide in vivo in which the T cells surive in vivo and remain tolerant as long as
antigen is present. If the anergic cells are transferred to a new host not expressing the
peptide , the cells regain responsiveness without proliferation. If the cells are transferred
; "
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to a new host expressing the antigen, they are induced into an even deeper level of anergy
(51). In the system described by Pape, et ai. , in which anergy is induced in TCR
transgenic cells in a normal host with peptide injection in the absence of adjuvant
anergic cells lose unresponsiveness after a period of time. This loss of responsiveness is
preceeded by a clearing of antigen in the host; if the tolerizing antigen is repeatedly
introduced into the host the anergic cells remain hyporesponsive longer than with a single
injection (49). I have also observed this loss of anergy in the A.E7 cell line over time and
it correlates with a loss of Egr-2 expression (data not shown). It is possible that Egr-
maintains the transcription of anergy effector molecules long-term, and that the loss of
Egr-2 expression explains the impermanence of anergy. Since even full stimulation of an
anergic cell is able to induce Egr-2 to maximal levels without inducing IL-2 transcription
or proliferation, maybe the presence of antigen in the in vivo models discussed above
maintains hyporesponsiveness long-term by repeatedly inducing Egr-2. Further work
should be done, including directly showing that inbitors of the MA kinase cascade do
not affect Egr-2 induction. I would be interested to know if Egr-2 expression correlates
with anergy and its decline in the in vivo systems. It would also be interesting to know, in
the injected peptide system of Tanchot et ai. , whether periodic exposure of the in vivo
anergic cells to peptide in a context of productive activation would also maintain anergy
over prolonged periods. I would hypothesize yes, if the rechallenge effect is due to Egr-
induction, since it is induced without proliferation even with full stimulation.
Third, concerning the role of Egr-2 in anergy in vitro, one could make a stable
transfectant of A.E7 T cells with Egr-2 expressed under an inducible promoter. This
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would allow observations to be made concernng direct and indirect roles of Egr-2 in IL-2
production, proliferation and the activation or repression of other genes.
Fourth is to stably transfect a vector containg hairin siRNA under an inducible
promoter into A.E7 T cells. This would allow inducible knockdown of Egr-2 without the
confounding effects of electroporation and the transience of siRNA. Hairpin siRNA
consists of a short transcript of antisense RNA similar to siRNA but also contains the
sense sequence in the reverse order separated from the antisense by 5-9 nucleotides. This
results in a transcript that acts similar to transiently transfected double stranded siRNA
because, with the 5-9 nucleotides as a hairin loop, the antisense and sense portions
anneal together. This has been reported to work well as a stable system to silence genes
(123).
Lastly, in order to study the effects of Egr-2 on anergy in vivo, an Egr-2 knockout
mouse would be valuable. The knockout mouse has been produced and reported but is
embryonic lethal due to defective hindbrain formation (124). The only way to study the
effect of eliminating Egr-2 on anergy in vivo would be to create a conditional knockout
mouse, lackig Egr-2 in only its T cells so that brain development and the development
of all other tissues is normal. However, this is a lengthy enterprise-for a description of
the method of makg a conditional knockout using the Cre/lox system, see the
publication by Brian Sauer (125). Fortnately, another group has already produced and
published a mouse with floxed Egr-2 in order to study brain development (126). I have
contacted P. Chamay, the corresponding author, and he has agreed to provide us with
these mice in a collaboration effort. Mice expressing Cre under a T cell-specific promoter
/;;. :..'.
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can be purchased and crossed to these mice, producing the conditional T cell Egr-
knockout. With this mouse, not only could anergy induced by various methods be studied
in vivo , but more complicated systems of tolerance could be examined for the role that
Egr-2 and anergy play.
Conclusions: Modified model of anergy
induction
T cell stimulation resulting in IL-2 production and proliferation requires two
signals-a TCR signal and an additive CD28 signal. TCR crosslinkng induces 3
downstream pathways: 1) Ras and Raf activation, activation of the MAP kinases ERK
JNK, and p38 , dimerization offos andjun transcription factors (AP- l), production of
Egr- , and their translocation into the nucleus; 2) generation ofDAG, activation of
protein kinase C (PKC) leading to the degradation ofIKB , and translocation ofNFKB into
the nucleus; 3) generation of IP3, release of calcium into the cell, activation of
calcineurin, and dephosphorylation and translocation ofNFAT into the nucleus. AP-
NFKB , and NF A T coactivate IL- 2 transcription while NF AT alone induces transcription
ofEgr-2. CD28 signaling strengthens the TCR signal possibly increasing NFKB
activation, prolonging the Ca ++ influx and, most importantly, stabilizing IL-2 mRA. IL-
2 production and autocrie signaling induces G 1 S phase transition and proliferation
which diminishes Egr-2 production. When Egr-2 production is shut down between 2 and
:0'
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5 days following stimulation, anergy effectors are not induced. These cells remain
responsive to rechallenge with antigen (Figure 23a).
TCR stimulation without CD28 co stimulation results in failure to produce IL-2
probably through suboptimal NFKB activation and IL-2 mRA instability. Because IL-2
production is not suffcient, proliferation does not occur and the Egr-2 protein level
remains elevated. As a result, Egr-2 activates other "anergy factors , effectors that
directly mediate anergic hyporesponsiveness. Candidate anergy factors with late
induction identified in the Affymetrix GeneChip screen include: 1) the EST AKOlll78
with potential Rho or Ras inactivating activity; 2) Pac- , a known MAP kinase
phosphatase; 3) Bace- , a membrane-bound secretase with unown fuction in T cells;
and 4) Neuritin, a GPI- linked protein with unown fuction in T cells (Figue 23b).
When anergic cells are rechallenged with both signals, NF A T is activated
normally. However, Ras and the MAP kiase cascade are inbited, fos, jun and Egr- l are
not induced and translocated into the nucleus, and IL-2 transcription may be actively
repressed. These effects are probably due to as yet unidentified anergy effector proteins;
any of the candidates described above may contribute to these fuctions. While activation
ofNFAT alone (and possibly NFKB) is insufficient for IL-2 production (failing to cause
proliferation), it is able to re- induce Egr-2 to maximal levels. This strengthens the anergic
state, which otherwise disappears coincident with the loss of Egr-2 (Figue 24).
While anergy is probably mediated by a number of factors that work in concert
Egr-2 may be a priary factor that activates a program of gene transcription inducing
effector molecules that mediate the many different aspects of the anergic phenotype
':,\ .
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observed, including hyporesponsiveness, differential homing, and cytokine production
(41;127). The fact that other studies have observed Egr-2 induction in tolerized
lymphocytes both in vitro and in vivo suggests that Egr-2 may function in anergy induced
by a variety of mechansms. Based on the data presented here, identifying the factors
controlled by Egr-2 in these models should provide important insights into the
mechanisms involved in the maintenance of immune tolerance.
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Legend to Figure 23: Model ofT cell activation and anergy induction. (A) T cell
stimulation through the TCR and CD28 results in IL-2 production, proliferation, and
anergy avoidance. (B) T cell stimulation through the TCR alone does not induce
suffcient IL-2 or proliferation and results in anergy induction.
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Legend to Figure 24: Model for failed proliferation following antigen rechallenge of
anergic cells. Even full stimulation of anergic cells does not induce IL-2 production or
proliferation. This is probably due to anergy effector proteins induced by sustained Egr-
expression. Egr-2 is re- induced in these cells, prolonging anergic hyporesponsiveness.
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